{
  "doc_id": "12",
  "paragraphs": [
    {
      "paragraph_id": "0",
      "paragraph": "二甲双胍临床应用专家共识",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍临床应用专家共识",
          "start_idx": 0,
          "end_idx": 12,
          "entities": [
            {
              "entity_id": "T0",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "1",
      "paragraph": "二甲双胍自1957年问世，应用于临床已有50多年的历史，是当前全球应用最广泛的口服降糖药之一。近年来有许多种新型降糖药物上市，但二甲双胍仍是在全球使用量迅速增加的经典口服降糖药物。二甲双胍具有良好的单药/联合治疗的疗效和安全性证据，以及良好的卫生经济学效益证据。无论对于血糖控制，还是糖尿病心血管并发症的预防，其都有明确的临床证据。因此，该药已成为全球控制糖尿病的核心药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍自1957年问世，应用于临床已有50多年的历史，是当前全球应用最广泛的口服降糖药之一。近年来有许多种新型降糖药物上市，但二甲双胍仍是在全球使用量迅速增加的经典口服降糖药物。二甲双胍具有良好的单药/联合治疗的疗效和安全性证据，以及良好的卫生经济学效益证据。无论对于血糖控制，还是糖尿病心血管并发症的预防，其都有明确的临床证据。",
          "start_idx": 0,
          "end_idx": 166,
          "entities": [
            {
              "entity_id": "T1",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T3",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 68
            },
            {
              "entity_id": "T4",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 94
            },
            {
              "entity_id": "T5",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 142,
              "end_idx": 145
            },
            {
              "entity_id": "T6",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 135,
              "end_idx": 137
            },
            {
              "entity_id": "T7",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 145,
              "end_idx": 148
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R0",
              "head_entity_id": "T6",
              "tail_entity_id": "T5"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R1",
              "head_entity_id": "T7",
              "tail_entity_id": "T5"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "因此，该药已成为全球控制糖尿病的核心药物。",
          "start_idx": 166,
          "end_idx": 187,
          "entities": [
            {
              "entity_id": "T2",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 15
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "2",
      "paragraph": "二甲双胍在我国已经有近20年的使用经验。1995年，FDA正式批准二甲双胍用于治疗T2DM，2004年欧盟正式批准二甲双胍用于治疗10岁以上的儿童T2DM。国内外主要糖尿病指南均建议：无论患者超重与否，除非有肾损害的证据或风险，否则均应从开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍，这体现了二甲双胍在糖尿病治疗中的“基石“地位。然而,在临床工作中，仍有部分医生和患者对二甲双胍的使用(有效性、剂量、用法、安全性、疗效与体重的关系等)存在误区，如因担心胃肠道反应未能发挥二甲双胍的剂量优势：因担心其损害肝肾功能和引起乳酸酸中毒等，使一些原本可从二甲双胍治疗中获益的患者错失治疗良机，为此，我们组织内分泌临床专家、药学专家共同制定《二甲双胍临床应用专家共识》，以指导临床医生和患者正确认识并合理使用二甲双胍。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二甲双胍在我国已经有近20年的使用经验。1995年，FDA正式批准二甲双胍用于治疗T2DM，2004年欧盟正式批准二甲双胍用于治疗10岁以上的儿童T2DM。国内外主要糖尿病指南均建议：无论患者超重与否，除非有肾损害的证据或风险，否则均应从开始就使用二甲双胍治疗，且联合治疗的方案中都应包括二甲双胍，这体现了二甲双胍在糖尿病治疗中的“基石“地位。然而,在临床工作中，仍有部分医生和患者对二甲双胍的使用(有效性、剂量、用法、安全性、疗效与体重的关系等)存在误区，如因担心胃肠道反应未能发挥二甲双胍的剂量优势：因担心其损害肝肾功能和引起乳酸酸中毒等，使一些原本可从二甲双胍治疗中获益的患者错失治疗良机，为此，我们组织内分泌临床专家、药学专家共同制定《二甲双胍临床应用专家共识》，以指导临床医生和患者正确认识并合理使用二甲双胍。",
          "start_idx": 0,
          "end_idx": 360,
          "entities": [
            {
              "entity_id": "T8",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            },
            {
              "entity_id": "T9",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 45
            },
            {
              "entity_id": "T10",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 41,
              "end_idx": 43
            },
            {
              "entity_id": "T11",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 73,
              "end_idx": 77
            },
            {
              "entity_id": "T12",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 73,
              "end_idx": 75
            },
            {
              "entity_id": "T13",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 61
            },
            {
              "entity_id": "T14",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 86
            },
            {
              "entity_id": "T15",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128
            },
            {
              "entity_id": "T16",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 148
            },
            {
              "entity_id": "T17",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 153,
              "end_idx": 157
            },
            {
              "entity_id": "T18",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 158,
              "end_idx": 161
            },
            {
              "entity_id": "T19",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 192,
              "end_idx": 196
            },
            {
              "entity_id": "T20",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 233,
              "end_idx": 238
            },
            {
              "entity_id": "T21",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 242,
              "end_idx": 246
            },
            {
              "entity_id": "T22",
              "entity": "损害肝肾功能",
              "entity_type": "ADE",
              "start_idx": 256,
              "end_idx": 262
            },
            {
              "entity_id": "T23",
              "entity": "乳酸酸中毒",
              "entity_type": "ADE",
              "start_idx": 265,
              "end_idx": 270
            },
            {
              "entity_id": "T24",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 279,
              "end_idx": 283
            },
            {
              "entity_id": "T25",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 322,
              "end_idx": 326
            },
            {
              "entity_id": "T26",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 355,
              "end_idx": 359
            },
            {
              "entity_id": "T27",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37
            },
            {
              "entity_id": "T28",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 98
            },
            {
              "entity_id": "T29",
              "entity": "肾损害",
              "entity_type": "Disease",
              "start_idx": 104,
              "end_idx": 107
            },
            {
              "entity_id": "T30",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 104,
              "end_idx": 105
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R2",
              "head_entity_id": "T10",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R3",
              "head_entity_id": "T27",
              "tail_entity_id": "T9"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R4",
              "head_entity_id": "T13",
              "tail_entity_id": "T11"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R5",
              "head_entity_id": "T12",
              "tail_entity_id": "T11"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R6",
              "head_entity_id": "T15",
              "tail_entity_id": "T14"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R7",
              "head_entity_id": "T16",
              "tail_entity_id": "T14"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R8",
              "head_entity_id": "T17",
              "tail_entity_id": "T18"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R9",
              "head_entity_id": "T20",
              "tail_entity_id": "T21"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R10",
              "head_entity_id": "T22",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R11",
              "head_entity_id": "T23",
              "tail_entity_id": "T24"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R12",
              "head_entity_id": "T30",
              "tail_entity_id": "T29"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "3",
      "paragraph": "循证医学证据分级、常见缩略语及主要推荐意见见表1~3。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "循证医学证据分级、常见缩略语及主要推荐意见见表1~3。",
          "start_idx": 0,
          "end_idx": 27,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "4",
      "paragraph": "一、临床地位与使用时机",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "一、临床地位与使用时机",
          "start_idx": 0,
          "end_idx": 11,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "5",
      "paragraph": "1.治疗T2DM的一线首选用药：二甲双胍具有可靠的短期和长期降糖疗效，单独使用可有效降低T2DM患者的FPG、PPG，可使HbA1c下降1%~2%，可使中国新诊断T2DM患者的HbA1c降低1.8%(可能含安慰剂效应)，且不受体重影响。在相似的基线HbA1c条件下，最佳有效剂量(2000mg/d)的降糖疗效显著强于其他口服降糖药。二甲双胍单药治疗疗效不佳的患者，联合其他口服降糖药可进一步获得明显的血糖改善(Ⅰ级)。联合胰岛素可降低血糖、改善血脂，同时减轻胰岛素引起的体重增加，减少胰岛素用量。该药具有心血管保护作用，是目前唯一被糖尿病指南推荐为有明确心血管获益证据的降糖药物。二甲双胍的长期治疗与新诊断的T2DM患者及已经发生了心血管疾病的T2DM患者的心血管疾病发生风险下降相关(Ⅰ级)。二甲双胍具有良好的安全性和耐受性，低血糖的发生率低，胃肠道反应多为一过性，不导致肾脏损害，长期使用不增加高乳酸血症和乳酸酸中毒的风险。与其他降糖药物相比，具有更好的成本效益比(Ⅰ级)。如无禁忌症，二甲双胍是T2DM药物治疗的首选药物，且应一直保留在糖尿病治疗方案中。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.治疗T2DM的一线首选用药：二甲双胍具有可靠的短期和长期降糖疗效，单独使用可有效降低T2DM患者的FPG、PPG，可使HbA1c下降1%~2%，可使中国新诊断T2DM患者的HbA1c降低1.8%(可能含安慰剂效应)，且不受体重影响。在相似的基线HbA1c条件下，最佳有效剂量(2000mg/d)的降糖疗效显著强于其他口服降糖药。二甲双胍单药治疗疗效不佳的患者，联合其他口服降糖药可进一步获得明显的血糖改善(Ⅰ级)。联合胰岛素可降低血糖、改善血脂，同时减轻胰岛素引起的体重增加，减少胰岛素用量。该药具有心血管保护作用，是目前唯一被糖尿病指南推荐为有明确心血管获益证据的降糖药物。二甲双胍的长期治疗与新诊断的T2DM患者及已经发生了心血管疾病的T2DM患者的心血管疾病发生风险下降相关(Ⅰ级)。二甲双胍具有良好的安全性和耐受性，低血糖的发生率低，胃肠道反应多为一过性，不导致肾脏损害，长期使用不增加高乳酸血症和乳酸酸中毒的风险。",
          "start_idx": 0,
          "end_idx": 414,
          "entities": [
            {
              "entity_id": "T31",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 8
            },
            {
              "entity_id": "T32",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 4,
              "end_idx": 6
            },
            {
              "entity_id": "T33",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 16,
              "end_idx": 20
            },
            {
              "entity_id": "T34",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 54
            },
            {
              "entity_id": "T35",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 55,
              "end_idx": 58
            },
            {
              "entity_id": "T36",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 61,
              "end_idx": 66
            },
            {
              "entity_id": "T37",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T38",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 46
            },
            {
              "entity_id": "T39",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 88,
              "end_idx": 93
            },
            {
              "entity_id": "T40",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 124,
              "end_idx": 129
            },
            {
              "entity_id": "T41",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 170
            },
            {
              "entity_id": "T42",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 200,
              "end_idx": 202
            },
            {
              "entity_id": "T43",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 211,
              "end_idx": 214
            },
            {
              "entity_id": "T44",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 217,
              "end_idx": 219
            },
            {
              "entity_id": "T45",
              "entity": "血脂",
              "entity_type": "Test",
              "start_idx": 222,
              "end_idx": 224
            },
            {
              "entity_id": "T46",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 229,
              "end_idx": 232
            },
            {
              "entity_id": "T47",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 242,
              "end_idx": 245
            },
            {
              "entity_id": "T48",
              "entity": "下降1%~2%",
              "entity_type": "Test_Value",
              "start_idx": 66,
              "end_idx": 73
            },
            {
              "entity_id": "T49",
              "entity": "降低1.8%",
              "entity_type": "Test_Value",
              "start_idx": 93,
              "end_idx": 99
            },
            {
              "entity_id": "T50",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 235,
              "end_idx": 239
            },
            {
              "entity_id": "T51",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 140,
              "end_idx": 148
            },
            {
              "entity_id": "T52",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 186,
              "end_idx": 188
            },
            {
              "entity_id": "T53",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 160,
              "end_idx": 162
            },
            {
              "entity_id": "T54",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 266,
              "end_idx": 269
            },
            {
              "entity_id": "T55",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 290,
              "end_idx": 294
            },
            {
              "entity_id": "T56",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 304,
              "end_idx": 308
            },
            {
              "entity_id": "T57",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 304,
              "end_idx": 306
            },
            {
              "entity_id": "T58",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 347,
              "end_idx": 351
            },
            {
              "entity_id": "T59",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 364,
              "end_idx": 367
            },
            {
              "entity_id": "T60",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 373,
              "end_idx": 378
            },
            {
              "entity_id": "T61",
              "entity": "肾脏损害",
              "entity_type": "ADE",
              "start_idx": 387,
              "end_idx": 391
            },
            {
              "entity_id": "T62",
              "entity": "高乳酸血症",
              "entity_type": "Disease",
              "start_idx": 399,
              "end_idx": 404
            },
            {
              "entity_id": "T63",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 405,
              "end_idx": 410
            },
            {
              "entity_id": "T68",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 316,
              "end_idx": 321
            },
            {
              "entity_id": "T69",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 316,
              "end_idx": 319
            },
            {
              "entity_id": "T70",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 329,
              "end_idx": 334
            },
            {
              "entity_id": "T71",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 329,
              "end_idx": 332
            },
            {
              "entity_id": "T72",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 81,
              "end_idx": 85
            },
            {
              "entity_id": "T73",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 81,
              "end_idx": 83
            },
            {
              "entity_id": "T74",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 322,
              "end_idx": 326
            },
            {
              "entity_id": "T75",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 322,
              "end_idx": 324
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R13",
              "head_entity_id": "T32",
              "tail_entity_id": "T31"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R14",
              "head_entity_id": "T33",
              "tail_entity_id": "T31"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R15",
              "head_entity_id": "T34",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R16",
              "head_entity_id": "T35",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R17",
              "head_entity_id": "T36",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R18",
              "head_entity_id": "T38",
              "tail_entity_id": "T37"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R19",
              "head_entity_id": "T39",
              "tail_entity_id": "T72"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R20",
              "head_entity_id": "T50",
              "tail_entity_id": "T46"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R21",
              "head_entity_id": "T55",
              "tail_entity_id": "T56"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R22",
              "head_entity_id": "T57",
              "tail_entity_id": "T56"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R23",
              "head_entity_id": "T59",
              "tail_entity_id": "T58"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R24",
              "head_entity_id": "T60",
              "tail_entity_id": "T58"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R27",
              "head_entity_id": "T69",
              "tail_entity_id": "T68"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R28",
              "head_entity_id": "T71",
              "tail_entity_id": "T70"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R29",
              "head_entity_id": "T73",
              "tail_entity_id": "T72"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R30",
              "head_entity_id": "T75",
              "tail_entity_id": "T74"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "与其他降糖药物相比，具有更好的成本效益比(Ⅰ级)。",
          "start_idx": 414,
          "end_idx": 439,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "如无禁忌症，二甲双胍是T2DM药物治疗的首选药物，且应一直保留在糖尿病治疗方案中。",
          "start_idx": 439,
          "end_idx": 480,
          "entities": [
            {
              "entity_id": "T64",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T65",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 11,
              "end_idx": 13
            },
            {
              "entity_id": "T66",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 35
            },
            {
              "entity_id": "T67",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R25",
              "head_entity_id": "T65",
              "tail_entity_id": "T64"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R26",
              "head_entity_id": "T67",
              "tail_entity_id": "T64"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "6",
      "paragraph": "2.超重或肥胖T2DM患者的首选用药：回顾性和前瞻性的临床研究结果均显示，二甲双胍在正常体重、超重、肥胖的T2DM患者中的疗效相当，",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.超重或肥胖T2DM患者的首选用药：回顾性和前瞻性的临床研究结果均显示，二甲双胍在正常体重、超重、肥胖的T2DM患者中的疗效相当，",
          "start_idx": 0,
          "end_idx": 66,
          "entities": [
            {
              "entity_id": "T76",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 11
            },
            {
              "entity_id": "T77",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 7,
              "end_idx": 9
            },
            {
              "entity_id": "T78",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T79",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 53,
              "end_idx": 55
            },
            {
              "entity_id": "T80",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T81",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 4
            },
            {
              "entity_id": "T82",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 7
            },
            {
              "entity_id": "T83",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 47,
              "end_idx": 49
            },
            {
              "entity_id": "T84",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 52
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R31",
              "head_entity_id": "T77",
              "tail_entity_id": "T76"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R32",
              "head_entity_id": "T79",
              "tail_entity_id": "T78"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R33",
              "head_entity_id": "T80",
              "tail_entity_id": "T78"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "7",
      "paragraph": "因此，体重不是使用二甲双胍治疗与否的决定因素(Ⅰ级)。无论对于超重患者还是体重正常的患者，国内外主要糖尿病指南均推荐二甲双胍为治疗T2DM的首选用药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "因此，体重不是使用二甲双胍治疗与否的决定因素(Ⅰ级)。无论对于超重患者还是体重正常的患者，国内外主要糖尿病指南均推荐二甲双胍为治疗T2DM的首选用药。",
          "start_idx": 0,
          "end_idx": 75,
          "entities": [
            {
              "entity_id": "T85",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13
            },
            {
              "entity_id": "T86",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 31,
              "end_idx": 33
            },
            {
              "entity_id": "T87",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 50,
              "end_idx": 53
            },
            {
              "entity_id": "T88",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T89",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 65,
              "end_idx": 67
            },
            {
              "entity_id": "T90",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R34",
              "head_entity_id": "T89",
              "tail_entity_id": "T88"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R35",
              "head_entity_id": "T90",
              "tail_entity_id": "T88"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "8",
      "paragraph": "3.对于糖尿病的预防作用：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物。二甲双胍能有效地降低糖尿病前期人群发生T2DM的风险，且具有良好的耐受性和长期的有效性。但在我国预防糖尿病尚不是二甲双胍的适应证。DPP研究显示，二甲双胍干预治疗3年可使糖尿病的发生率降低31%，且在中年腹型肥胖的患者中干预效果最佳(Ⅰ级)。IDPP研究显示，二甲双胍单独或与强化生活方式干预联合应用均能降低发生糖尿病的危险(Ⅱ级)。2012年IDF全球T2DM指南推荐，预防糖尿病最好选择生活方式干预，对于IFG、年龄<60岁的肥胖人群，可给予二甲双胍干预。DPP研究随访显示，生活方式干预组和二甲双胍治疗组与安慰剂组相比，10年内糖尿病病发生率分别降低了34%和18%(Ⅰ级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.对于糖尿病的预防作用：二甲双胍是第一个被证明能预防糖尿病或延缓糖尿病发生的药物。二甲双胍能有效地降低糖尿病前期人群发生T2DM的风险，且具有良好的耐受性和长期的有效性。但在我国预防糖尿病尚不是二甲双胍的适应证。DPP研究显示，二甲双胍干预治疗3年可使糖尿病的发生率降低31%，且在中年腹型肥胖的患者中干预效果最佳(Ⅰ级)。IDPP研究显示，二甲双胍单独或与强化生活方式干预联合应用均能降低发生糖尿病的危险(Ⅱ级)。2012年IDF全球T2DM指南推荐，预防糖尿病最好选择生活方式干预，对于IFG、年龄<60岁的肥胖人群，可给予二甲双胍干预。",
          "start_idx": 0,
          "end_idx": 272,
          "entities": [
            {
              "entity_id": "T91",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7
            },
            {
              "entity_id": "T92",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17
            },
            {
              "entity_id": "T93",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 27,
              "end_idx": 30
            },
            {
              "entity_id": "T94",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 36
            },
            {
              "entity_id": "T95",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46
            },
            {
              "entity_id": "T96",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 65
            },
            {
              "entity_id": "T97",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 61,
              "end_idx": 63
            },
            {
              "entity_id": "T98",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 92,
              "end_idx": 95
            },
            {
              "entity_id": "T99",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 98,
              "end_idx": 102
            },
            {
              "entity_id": "T100",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 127,
              "end_idx": 130
            },
            {
              "entity_id": "T101",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 115,
              "end_idx": 119
            },
            {
              "entity_id": "T102",
              "entity": "腹型肥胖",
              "entity_type": "Disease",
              "start_idx": 144,
              "end_idx": 148
            },
            {
              "entity_id": "T103",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 172,
              "end_idx": 176
            },
            {
              "entity_id": "T104",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 198,
              "end_idx": 201
            },
            {
              "entity_id": "T105",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 219,
              "end_idx": 223
            },
            {
              "entity_id": "T106",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 219,
              "end_idx": 221
            },
            {
              "entity_id": "T107",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 230,
              "end_idx": 233
            },
            {
              "entity_id": "T108",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 257,
              "end_idx": 259
            },
            {
              "entity_id": "T109",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 265,
              "end_idx": 269
            },
            {
              "entity_id": "T110",
              "entity": "IFG",
              "entity_type": "Disease",
              "start_idx": 246,
              "end_idx": 249
            },
            {
              "entity_id": "T112",
              "entity": "糖尿病前期",
              "entity_type": "Disease",
              "start_idx": 52,
              "end_idx": 57
            },
            {
              "entity_id": "T114",
              "entity": "腹型",
              "entity_type": "Class",
              "start_idx": 144,
              "end_idx": 146
            },
            {
              "entity_id": "T115",
              "entity": "前期",
              "entity_type": "Class",
              "start_idx": 55,
              "end_idx": 57
            },
            {
              "entity_id": "T116",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 182,
              "end_idx": 188
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R36",
              "head_entity_id": "T92",
              "tail_entity_id": "T93"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R37",
              "head_entity_id": "T92",
              "tail_entity_id": "T94"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R38",
              "head_entity_id": "T95",
              "tail_entity_id": "T112"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R39",
              "head_entity_id": "T95",
              "tail_entity_id": "T96"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R40",
              "head_entity_id": "T97",
              "tail_entity_id": "T96"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R41",
              "head_entity_id": "T99",
              "tail_entity_id": "T98"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R42",
              "head_entity_id": "T101",
              "tail_entity_id": "T100"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R43",
              "head_entity_id": "T101",
              "tail_entity_id": "T102"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R44",
              "head_entity_id": "T114",
              "tail_entity_id": "T102"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R45",
              "head_entity_id": "T103",
              "tail_entity_id": "T104"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R46",
              "head_entity_id": "T116",
              "tail_entity_id": "T104"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R47",
              "head_entity_id": "T106",
              "tail_entity_id": "T105"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R48",
              "head_entity_id": "T109",
              "tail_entity_id": "T107"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R49",
              "head_entity_id": "T109",
              "tail_entity_id": "T108"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R50",
              "head_entity_id": "T109",
              "tail_entity_id": "T110"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R52",
              "head_entity_id": "T115",
              "tail_entity_id": "T112"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "DPP研究随访显示，生活方式干预组和二甲双胍治疗组与安慰剂组相比，10年内糖尿病病发生率分别降低了34%和18%(Ⅰ级)。",
          "start_idx": 272,
          "end_idx": 333,
          "entities": [
            {
              "entity_id": "T111",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22
            },
            {
              "entity_id": "T113",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 37,
              "end_idx": 40
            },
            {
              "entity_id": "T117",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 10,
              "end_idx": 16
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R51",
              "head_entity_id": "T111",
              "tail_entity_id": "T113"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R53",
              "head_entity_id": "T117",
              "tail_entity_id": "T113"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "9",
      "paragraph": "二、作用机制",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "二、作用机制",
          "start_idx": 0,
          "end_idx": 6,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "10",
      "paragraph": "1.二甲双胍的降糖作用机制：二甲双胍治疗糖尿病的作用机制包括(1)通过直接抑制肝脏的糖异生降低FPG；(2)通过提高外周组织(肌肉、脂肪)对葡萄糖的摄取和利用，降低PPG；(3)减少小肠内葡萄糖吸收；(4)通过抑制线粒体复合物Ⅰ和线粒体氧化磷酸化，减少ATP合成，激活AMPK，促进脂肪酸进入线粒体进行脂肪酸β氧化，减少脂肪合成，从而减轻IR；(5)改善IS，提高胰岛β细胞对血糖的应答；(6)升高GLP-1水平。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.二甲双胍的降糖作用机制：二甲双胍治疗糖尿病的作用机制包括(1)通过直接抑制肝脏的糖异生降低FPG；(2)通过提高外周组织(肌肉、脂肪)对葡萄糖的摄取和利用，降低PPG；(3)减少小肠内葡萄糖吸收；(4)通过抑制线粒体复合物Ⅰ和线粒体氧化磷酸化，减少ATP合成，激活AMPK，促进脂肪酸进入线粒体进行脂肪酸β氧化，减少脂肪合成，从而减轻IR；(5)改善IS，提高胰岛β细胞对血糖的应答；(6)升高GLP-1水平。",
          "start_idx": 0,
          "end_idx": 207,
          "entities": [
            {
              "entity_id": "T118",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T119",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23
            },
            {
              "entity_id": "T120",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 18
            },
            {
              "entity_id": "T121",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 47,
              "end_idx": 50
            },
            {
              "entity_id": "T122",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 85
            },
            {
              "entity_id": "T123",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 188,
              "end_idx": 190
            },
            {
              "entity_id": "T124",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 169,
              "end_idx": 171
            },
            {
              "entity_id": "T125",
              "entity": "GLP-1",
              "entity_type": "Test_items",
              "start_idx": 199,
              "end_idx": 204
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R54",
              "head_entity_id": "T120",
              "tail_entity_id": "T119"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R55",
              "head_entity_id": "T121",
              "tail_entity_id": "T119"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R56",
              "head_entity_id": "T122",
              "tail_entity_id": "T119"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R57",
              "head_entity_id": "T123",
              "tail_entity_id": "T119"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R58",
              "head_entity_id": "T125",
              "tail_entity_id": "T119"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R59",
              "head_entity_id": "T124",
              "tail_entity_id": "T119"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "11",
      "paragraph": "2.二甲双胍是一种胰岛素增敏剂：《Joslin糖尿病学》将二甲双胍归为增敏剂一类。IR是T2DM的主要病理生理特征之一。机体在IR的代偿反应是分泌更多的胰岛素，以维持正常的糖代谢。胰岛素增敏剂通过改善IR，增加胰岛素刺激的葡萄糖利用，减少脂肪酸氧化代谢，抑制肝糖输出。二甲双胍通过抑制肝糖原分解，降低肝糖异生，增强胰岛素与外周组织胰岛素受体的亲合力，促进葡萄糖的摄取和利用，改善组织对胰岛素的敏感性。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.二甲双胍是一种胰岛素增敏剂：《Joslin糖尿病学》将二甲双胍归为增敏剂一类。IR是T2DM的主要病理生理特征之一。",
          "start_idx": 0,
          "end_idx": 60,
          "entities": [
            {
              "entity_id": "T126",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T127",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T128",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 33
            },
            {
              "entity_id": "T129",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T130",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 46
            },
            {
              "entity_id": "T131",
              "entity": "胰岛素增敏剂",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 15
            },
            {
              "entity_id": "T136",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 41,
              "end_idx": 43
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R60",
              "head_entity_id": "T128",
              "tail_entity_id": "T127"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R61",
              "head_entity_id": "T130",
              "tail_entity_id": "T129"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R62",
              "head_entity_id": "T136",
              "tail_entity_id": "T129"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "机体在IR的代偿反应是分泌更多的胰岛素，以维持正常的糖代谢。",
          "start_idx": 60,
          "end_idx": 90,
          "entities": [
            {
              "entity_id": "T134",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 3,
              "end_idx": 5
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "胰岛素增敏剂通过改善IR，增加胰岛素刺激的葡萄糖利用，减少脂肪酸氧化代谢，抑制肝糖输出。",
          "start_idx": 90,
          "end_idx": 134,
          "entities": [
            {
              "entity_id": "T132",
              "entity": "胰岛素增敏剂",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 6
            },
            {
              "entity_id": "T135",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 10,
              "end_idx": 12
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "二甲双胍通过抑制肝糖原分解，降低肝糖异生，增强胰岛素与外周组织胰岛素受体的亲合力，促进葡萄糖的摄取和利用，改善组织对胰岛素的敏感性。",
          "start_idx": 134,
          "end_idx": 200,
          "entities": [
            {
              "entity_id": "T133",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "12",
      "paragraph": "三、剂量与临床疗效",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "三、剂量与临床疗效",
          "start_idx": 0,
          "end_idx": 9,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "13",
      "paragraph": "1.最小、最大及最佳使用剂量：二甲双胍的降糖效果与剂量(500~2000mg/d)呈正相关。500mg/d二甲双胍可降低HbA1c0.6%(减去安慰剂效应后，以下同)，2000mg/d可降低HbA1c2%，且胃肠道反应与1000或1500mg/d差异无统计学意义(Ⅰ级)。UKPDS研究中二甲双胍强化治疗剂量中位数达到2550mg/d，缓释剂型推荐最大用量为2000mg/d，普通片推荐成人最大剂量为2550mg/d。二甲双胍起效的最小推荐剂量500mg/d，成人最大量2550mg/d，最佳有效剂量2000mg/d。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.最小、最大及最佳使用剂量：二甲双胍的降糖效果与剂量(500~2000mg/d)呈正相关。500mg/d二甲双胍可降低HbA1c0.6%(减去安慰剂效应后，以下同)，2000mg/d可降低HbA1c2%，且胃肠道反应与1000或1500mg/d差异无统计学意义(Ⅰ级)。UKPDS研究中二甲双胍强化治疗剂量中位数达到2550mg/d，缓释剂型推荐最大用量为2000mg/d，普通片推荐成人最大剂量为2550mg/d。二甲双胍起效的最小推荐剂量500mg/d，成人最大量2550mg/d，最佳有效剂量2000mg/d。",
          "start_idx": 0,
          "end_idx": 259,
          "entities": [
            {
              "entity_id": "T137",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T138",
              "entity": "500mg/d",
              "entity_type": "Amount",
              "start_idx": 46,
              "end_idx": 53
            },
            {
              "entity_id": "T139",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T140",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 65
            },
            {
              "entity_id": "T141",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 84,
              "end_idx": 92
            },
            {
              "entity_id": "T142",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 104,
              "end_idx": 109
            },
            {
              "entity_id": "T143",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 148
            },
            {
              "entity_id": "T144",
              "entity": "2550mg/d",
              "entity_type": "Amount",
              "start_idx": 159,
              "end_idx": 167
            },
            {
              "entity_id": "T145",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 179,
              "end_idx": 187
            },
            {
              "entity_id": "T146",
              "entity": "2550mg/d",
              "entity_type": "Amount",
              "start_idx": 200,
              "end_idx": 208
            },
            {
              "entity_id": "T147",
              "entity": "500mg/d",
              "entity_type": "Amount",
              "start_idx": 222,
              "end_idx": 229
            },
            {
              "entity_id": "T148",
              "entity": "2550mg/d",
              "entity_type": "Amount",
              "start_idx": 235,
              "end_idx": 243
            },
            {
              "entity_id": "T149",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 250,
              "end_idx": 258
            },
            {
              "entity_id": "T150",
              "entity": "1000或1500mg/d",
              "entity_type": "Amount",
              "start_idx": 110,
              "end_idx": 123
            },
            {
              "entity_id": "T151",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 95,
              "end_idx": 100
            },
            {
              "entity_id": "T152",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 209,
              "end_idx": 213
            },
            {
              "entity_id": "T153",
              "entity": "0.6%",
              "entity_type": "Test_Value",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T154",
              "entity": "2%",
              "entity_type": "Test_Value",
              "start_idx": 100,
              "end_idx": 102
            },
            {
              "entity_id": "T155",
              "entity": "500~2000mg/d",
              "entity_type": "Amount",
              "start_idx": 28,
              "end_idx": 40
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R63",
              "head_entity_id": "T155",
              "tail_entity_id": "T137"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R64",
              "head_entity_id": "T138",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R65",
              "head_entity_id": "T141",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R66",
              "head_entity_id": "T150",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R67",
              "head_entity_id": "T142",
              "tail_entity_id": "T139"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R68",
              "head_entity_id": "T144",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R69",
              "head_entity_id": "T145",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R70",
              "head_entity_id": "T146",
              "tail_entity_id": "T143"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R71",
              "head_entity_id": "T147",
              "tail_entity_id": "T152"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R72",
              "head_entity_id": "T148",
              "tail_entity_id": "T152"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R73",
              "head_entity_id": "T149",
              "tail_entity_id": "T152"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "14",
      "paragraph": "2.剂量调整原则：二甲双胍的剂量调整原则为“小剂量起始，逐渐加量”。开始时服用500mg/d或<1000mg/d，1~2周后加量至1000mg/d，继续1~2周加量1次。最佳剂量为2000mg/d(1000mg，2次/d或2000mg/d，3次/d)。二甲双胍可在进餐时或餐后立即服用，缓释剂型1次/d，晚餐时或餐后立即服用。考虑药物的临床疗效及患者依从性，可采用简化的剂量方案：建议起始500mg，2次/d，如无明显胃肠道不良反应，2周后可增加至1000mg，2次/d可根据患者状况个体化治疗，每日总剂量1500~2550mg，分2~3次服用。老年人及肝肾功能不全的患者需要调整剂量，具体调整方法详见“四”中，二甲双胍在特殊人群的使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.剂量调整原则：二甲双胍的剂量调整原则为“小剂量起始，逐渐加量”。开始时服用500mg/d或<1000mg/d，1~2周后加量至1000mg/d，继续1~2周加量1次。最佳剂量为2000mg/d(1000mg，2次/d或2000mg/d，3次/d)。二甲双胍可在进餐时或餐后立即服用，缓释剂型1次/d，晚餐时或餐后立即服用。考虑药物的临床疗效及患者依从性，可采用简化的剂量方案：建议起始500mg，2次/d，如无明显胃肠道不良反应，2周后可增加至1000mg，2次/d可根据患者状况个体化治疗，每日总剂量1500~2550mg，分2~3次服用。老年人及肝肾功能不全的患者需要调整剂量，具体调整方法详见“四”中，二甲双胍在特殊人群的使用。",
          "start_idx": 0,
          "end_idx": 319,
          "entities": [
            {
              "entity_id": "T156",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13
            },
            {
              "entity_id": "T157",
              "entity": "500mg/d",
              "entity_type": "Amount",
              "start_idx": 39,
              "end_idx": 46
            },
            {
              "entity_id": "T158",
              "entity": "<1000mg/d",
              "entity_type": "Amount",
              "start_idx": 47,
              "end_idx": 56
            },
            {
              "entity_id": "T159",
              "entity": "1000mg/d",
              "entity_type": "Amount",
              "start_idx": 65,
              "end_idx": 73
            },
            {
              "entity_id": "T160",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 90,
              "end_idx": 98
            },
            {
              "entity_id": "T161",
              "entity": "1000mg",
              "entity_type": "Amount",
              "start_idx": 99,
              "end_idx": 105
            },
            {
              "entity_id": "T162",
              "entity": "2次/d",
              "entity_type": "Frequency",
              "start_idx": 106,
              "end_idx": 110
            },
            {
              "entity_id": "T163",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 111,
              "end_idx": 119
            },
            {
              "entity_id": "T164",
              "entity": "3次/d",
              "entity_type": "Frequency",
              "start_idx": 120,
              "end_idx": 124
            },
            {
              "entity_id": "T165",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 126,
              "end_idx": 130
            },
            {
              "entity_id": "T166",
              "entity": "进餐时或餐后立即服用",
              "entity_type": "Method",
              "start_idx": 132,
              "end_idx": 142
            },
            {
              "entity_id": "T167",
              "entity": "1次/d",
              "entity_type": "Frequency",
              "start_idx": 147,
              "end_idx": 151
            },
            {
              "entity_id": "T168",
              "entity": "500mg",
              "entity_type": "Amount",
              "start_idx": 194,
              "end_idx": 199
            },
            {
              "entity_id": "T169",
              "entity": "2次/d",
              "entity_type": "Frequency",
              "start_idx": 200,
              "end_idx": 204
            },
            {
              "entity_id": "T170",
              "entity": "1000mg",
              "entity_type": "Amount",
              "start_idx": 224,
              "end_idx": 230
            },
            {
              "entity_id": "T171",
              "entity": "2次/d",
              "entity_type": "Frequency",
              "start_idx": 231,
              "end_idx": 235
            },
            {
              "entity_id": "T172",
              "entity": "胃肠道不良反应",
              "entity_type": "ADE",
              "start_idx": 209,
              "end_idx": 216
            },
            {
              "entity_id": "T173",
              "entity": "晚餐时或餐后立即服用",
              "entity_type": "Method",
              "start_idx": 152,
              "end_idx": 162
            },
            {
              "entity_id": "T174",
              "entity": "1500~2550mg",
              "entity_type": "Amount",
              "start_idx": 253,
              "end_idx": 264
            },
            {
              "entity_id": "T175",
              "entity": "分2~3次",
              "entity_type": "Frequency",
              "start_idx": 265,
              "end_idx": 270
            },
            {
              "entity_id": "T176",
              "entity": "肝肾功能不全",
              "entity_type": "Disease",
              "start_idx": 277,
              "end_idx": 283
            },
            {
              "entity_id": "T177",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 306,
              "end_idx": 310
            },
            {
              "entity_id": "T178",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 277,
              "end_idx": 278
            },
            {
              "entity_id": "T179",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 278,
              "end_idx": 279
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R74",
              "head_entity_id": "T166",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R75",
              "head_entity_id": "T173",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R76",
              "head_entity_id": "T167",
              "tail_entity_id": "T165"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R77",
              "head_entity_id": "T178",
              "tail_entity_id": "T176"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R78",
              "head_entity_id": "T179",
              "tail_entity_id": "T176"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "15",
      "paragraph": "3.剂型：目前国内外主要有单一成分的二甲双胍普通片(250mg/片，500mg/片或850rag/片)、二甲双胍缓释片或胶囊(500mg/片或500mg/胶囊)、二甲双胍肠溶片或胶囊(250mg/片或250mg/胶囊)、二甲双胍粉剂，以及与其他口服降糖药[如磺脲类药物或DPP-4抑制剂]组成的复方制剂。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.剂型：目前国内外主要有单一成分的二甲双胍普通片(250mg/片，500mg/片或850rag/片)、二甲双胍缓释片或胶囊(500mg/片或500mg/胶囊)、二甲双胍肠溶片或胶囊(250mg/片或250mg/胶囊)、二甲双胍粉剂，以及与其他口服降糖药[如磺脲类药物或DPP-4抑制剂]组成的复方制剂。",
          "start_idx": 0,
          "end_idx": 152,
          "entities": [
            {
              "entity_id": "T180",
              "entity": "二甲双胍粉剂",
              "entity_type": "Drug",
              "start_idx": 110,
              "end_idx": 116
            },
            {
              "entity_id": "T181",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 134
            },
            {
              "entity_id": "T182",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 143
            },
            {
              "entity_id": "T183",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 122,
              "end_idx": 124
            },
            {
              "entity_id": "T184",
              "entity": "二甲双胍普通片",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 25
            },
            {
              "entity_id": "T185",
              "entity": "二甲双胍缓释片或胶囊",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 62
            },
            {
              "entity_id": "T186",
              "entity": "二甲双胍肠溶片或胶囊",
              "entity_type": "Drug",
              "start_idx": 81,
              "end_idx": 91
            }
          ],
          "relations": [
            {
              "relation_type": "Method_Drug",
              "relation_id": "R79",
              "head_entity_id": "T183",
              "tail_entity_id": "T181"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R80",
              "head_entity_id": "T183",
              "tail_entity_id": "T182"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "16",
      "paragraph": "4.不同剂型的疗效区别：(1)各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同。普通片剂在胃内崩解释放；肠溶片在从胃排空到肠道后崩解释放；缓释片和缓释胶囊在肠道内缓慢地溶出、释放；肠溶胶囊在肠道内溶出、释放；(2)普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之。因每种制剂给药后血药浓度峰值、达峰时间、表观半衰期等参数存在一定的差异，所以多剂量给药后的达稳时间也不一致；(3)缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性；(4)合格的药物制剂，在相同的给药剂量下，各种剂型间应具有生物等效性；(5)不同剂型的临床疗效是否一致，尚需更多的大样本临床研究证实。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.不同剂型的疗效区别：(1)各种剂型的主要区别在于给药后制剂中药物的溶出释放行为不同。",
          "start_idx": 0,
          "end_idx": 44,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "普通片剂在胃内崩解释放；肠溶片在从胃排空到肠道后崩解释放；缓释片和缓释胶囊在肠道内缓慢地溶出、释放；肠溶胶囊在肠道内溶出、释放；(2)普通片剂在胃内的溶出速度较快，肠溶片和肠溶胶囊次之，缓释片再次之。",
          "start_idx": 44,
          "end_idx": 144,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "因每种制剂给药后血药浓度峰值、达峰时间、表观半衰期等参数存在一定的差异，所以多剂量给药后的达稳时间也不一致；(3)缓释片/胶囊和肠溶片/胶囊相对于普通片剂而言，可减少给药后的胃肠道反应，提高患者的用药依从性；(4)合格的药物制剂，在相同的给药剂量下，各种剂型间应具有生物等效性；(5)不同剂型的临床疗效是否一致，尚需更多的大样本临床研究证实。",
          "start_idx": 144,
          "end_idx": 315,
          "entities": [
            {
              "entity_id": "T187",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 87,
              "end_idx": 92
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "17",
      "paragraph": "5.单药治疗的降糖疗效：一项双盲、安慰剂对照、剂量效应研究显示，在减去安慰剂效应后，不同剂量的二甲双胍单药治疗可使FPG降低1.05~4.33mmol/L，HbA1c下降0.9%~2.o%。另有研究显示，二甲双胍可使PPG降低2.58mmol/L。中国新诊断T2DM患者中，二甲双胍可使HbA1c降低1.8%(可能含安慰剂效应)(Ⅰ级)。在新诊断的经过短期胰岛素治疗后的中国T2DM患者中开展的随机分组、前瞻性对照研究结果显示，二甲双胍(2000mg/d)的疗效与甘精胰岛素的降糖疗效相当。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.单药治疗的降糖疗效：一项双盲、安慰剂对照、剂量效应研究显示，在减去安慰剂效应后，不同剂量的二甲双胍单药治疗可使FPG降低1.05~4.33mmol/L，HbA1c下降0.9%~2.o%。另有研究显示，二甲双胍可使PPG降低2.58mmol/L。中国新诊断T2DM患者中，二甲双胍可使HbA1c降低1.8%(可能含安慰剂效应)(Ⅰ级)。在新诊断的经过短期胰岛素治疗后的中国T2DM患者中开展的随机分组、前瞻性对照研究结果显示，二甲双胍(2000mg/d)的疗效与甘精胰岛素的降糖疗效相当。",
          "start_idx": 0,
          "end_idx": 245,
          "entities": [
            {
              "entity_id": "T188",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51
            },
            {
              "entity_id": "T189",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 60
            },
            {
              "entity_id": "T190",
              "entity": "降低1.05~4.33mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 60,
              "end_idx": 77
            },
            {
              "entity_id": "T191",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 78,
              "end_idx": 83
            },
            {
              "entity_id": "T192",
              "entity": "下降0.9%~2.o%",
              "entity_type": "Test_Value",
              "start_idx": 83,
              "end_idx": 94
            },
            {
              "entity_id": "T193",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 102,
              "end_idx": 106
            },
            {
              "entity_id": "T194",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 108,
              "end_idx": 111
            },
            {
              "entity_id": "T195",
              "entity": "降低2.58mmol/L",
              "entity_type": "Test_Value",
              "start_idx": 111,
              "end_idx": 123
            },
            {
              "entity_id": "T196",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 129,
              "end_idx": 133
            },
            {
              "entity_id": "T197",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 129,
              "end_idx": 131
            },
            {
              "entity_id": "T198",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 141
            },
            {
              "entity_id": "T199",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 143,
              "end_idx": 148
            },
            {
              "entity_id": "T200",
              "entity": "降低1.8%",
              "entity_type": "Test_Value",
              "start_idx": 148,
              "end_idx": 154
            },
            {
              "entity_id": "T201",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 191
            },
            {
              "entity_id": "T202",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 187,
              "end_idx": 189
            },
            {
              "entity_id": "T203",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 178,
              "end_idx": 181
            },
            {
              "entity_id": "T204",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 214,
              "end_idx": 218
            },
            {
              "entity_id": "T205",
              "entity": "甘精胰岛素",
              "entity_type": "Drug",
              "start_idx": 232,
              "end_idx": 237
            },
            {
              "entity_id": "T206",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 219,
              "end_idx": 227
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R81",
              "head_entity_id": "T197",
              "tail_entity_id": "T196"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R82",
              "head_entity_id": "T198",
              "tail_entity_id": "T196"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R83",
              "head_entity_id": "T199",
              "tail_entity_id": "T196"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R84",
              "head_entity_id": "T202",
              "tail_entity_id": "T201"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R85",
              "head_entity_id": "T203",
              "tail_entity_id": "T201"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R86",
              "head_entity_id": "T206",
              "tail_entity_id": "T204"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "18",
      "paragraph": "6.联合磺脲类药物的疗效：二甲双胍可改善IR，降低肝糖输出，磺脲类药物可促进胰岛素分泌，两类药物联合，作用机制互补，具有更全面针对T2DM的病理生理缺陷的特点。一项随机、双盲、平行对照研究显示，二甲双胍联合格列本脲治疗组比单用二甲双胍或单用格列本脲组能更好地控制FPG和HbA1c。针对磺脲类药物血糖控制不佳的患者治疗18周后，格列吡嗪/二甲双胍复合制剂治疗组的血糖达标率(HbA1c<7.0%)为36.3%，分别是单用二甲双胍治疗组(8.9%)和单用格列吡嗪治疗组(9.9%)的4.1和3.7倍，同时可更好地控制FPG(Ⅰ级)。在中国T2DM患者中开展的一项随机、平行对照研究显示，二甲双胍联合格列喹酮治疗组的HbA1c降幅(1.7%)显著高于二甲双胍联合阿卡波糖治疗组的HbA1c降幅(0.9%)，且两组间低血糖、体重增加无差异无统计学意义。另有随机、双盲、双模拟、平行对照研究显示，在二甲双胍的基础上联合含有格列本脲的中药固定复方制剂与相同剂量的格列本脲相比，降糖效果相当，但低血糖发生的风险显著减低。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.联合磺脲类药物的疗效：二甲双胍可改善IR，降低肝糖输出，磺脲类药物可促进胰岛素分泌，两类药物联合，作用机制互补，具有更全面针对T2DM的病理生理缺陷的特点。一项随机、双盲、平行对照研究显示，二甲双胍联合格列本脲治疗组比单用二甲双胍或单用格列本脲组能更好地控制FPG和HbA1c。针对磺脲类药物血糖控制不佳的患者治疗18周后，格列吡嗪/二甲双胍复合制剂治疗组的血糖达标率(HbA1c<7.0%)为36.3%，分别是单用二甲双胍治疗组(8.9%)和单用格列吡嗪治疗组(9.9%)的4.1和3.7倍，同时可更好地控制FPG(Ⅰ级)。在中国T2DM患者中开展的一项随机、平行对照研究显示，二甲双胍联合格列喹酮治疗组的HbA1c降幅(1.7%)显著高于二甲双胍联合阿卡波糖治疗组的HbA1c降幅(0.9%)，且两组间低血糖、体重增加无差异无统计学意义。另有随机、双盲、双模拟、平行对照研究显示，在二甲双胍的基础上联合含有格列本脲的中药固定复方制剂与相同剂量的格列本脲相比，降糖效果相当，但低血糖发生的风险显著减低。",
          "start_idx": 0,
          "end_idx": 454,
          "entities": [
            {
              "entity_id": "T207",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T208",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 65,
              "end_idx": 67
            },
            {
              "entity_id": "T209",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17
            },
            {
              "entity_id": "T210",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 30,
              "end_idx": 35
            },
            {
              "entity_id": "T211",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 9
            },
            {
              "entity_id": "T212",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 97,
              "end_idx": 101
            },
            {
              "entity_id": "T213",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 107
            },
            {
              "entity_id": "T214",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 117
            },
            {
              "entity_id": "T215",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 120,
              "end_idx": 124
            },
            {
              "entity_id": "T216",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 131,
              "end_idx": 134
            },
            {
              "entity_id": "T217",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 135,
              "end_idx": 140
            },
            {
              "entity_id": "T218",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 148
            },
            {
              "entity_id": "T219",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 148,
              "end_idx": 150
            },
            {
              "entity_id": "T220",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 164,
              "end_idx": 168
            },
            {
              "entity_id": "T221",
              "entity": "二甲双胍复合制剂",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 177
            },
            {
              "entity_id": "T222",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 181,
              "end_idx": 183
            },
            {
              "entity_id": "T223",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 187,
              "end_idx": 192
            },
            {
              "entity_id": "T224",
              "entity": "<7.0%",
              "entity_type": "Test_Value",
              "start_idx": 192,
              "end_idx": 197
            },
            {
              "entity_id": "T225",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 210,
              "end_idx": 214
            },
            {
              "entity_id": "T226",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 226,
              "end_idx": 230
            },
            {
              "entity_id": "T227",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 257,
              "end_idx": 260
            },
            {
              "entity_id": "T228",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 292,
              "end_idx": 296
            },
            {
              "entity_id": "T229",
              "entity": "格列喹酮",
              "entity_type": "Drug",
              "start_idx": 298,
              "end_idx": 302
            },
            {
              "entity_id": "T230",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 306,
              "end_idx": 311
            },
            {
              "entity_id": "T231",
              "entity": "降幅(1.7%)",
              "entity_type": "Test_Value",
              "start_idx": 311,
              "end_idx": 319
            },
            {
              "entity_id": "T232",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 323,
              "end_idx": 327
            },
            {
              "entity_id": "T233",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 329,
              "end_idx": 333
            },
            {
              "entity_id": "T234",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 337,
              "end_idx": 342
            },
            {
              "entity_id": "T235",
              "entity": "降幅(0.9%)",
              "entity_type": "Test_Value",
              "start_idx": 342,
              "end_idx": 350
            },
            {
              "entity_id": "T236",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 355,
              "end_idx": 358
            },
            {
              "entity_id": "T237",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 395,
              "end_idx": 399
            },
            {
              "entity_id": "T238",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 407,
              "end_idx": 411
            },
            {
              "entity_id": "T239",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 441,
              "end_idx": 444
            },
            {
              "entity_id": "T240",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 426,
              "end_idx": 430
            },
            {
              "entity_id": "T241",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 20,
              "end_idx": 22
            },
            {
              "entity_id": "T242",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 268,
              "end_idx": 272
            },
            {
              "entity_id": "T243",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 268,
              "end_idx": 270
            },
            {
              "entity_id": "T244",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 359,
              "end_idx": 363
            },
            {
              "entity_id": "T245",
              "entity": "控制不佳",
              "entity_type": "Test_Value",
              "start_idx": 150,
              "end_idx": 154
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R87",
              "head_entity_id": "T208",
              "tail_entity_id": "T207"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R88",
              "head_entity_id": "T209",
              "tail_entity_id": "T207"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R89",
              "head_entity_id": "T210",
              "tail_entity_id": "T207"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R90",
              "head_entity_id": "T241",
              "tail_entity_id": "T207"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R91",
              "head_entity_id": "T228",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R92",
              "head_entity_id": "T244",
              "tail_entity_id": "T228"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R93",
              "head_entity_id": "T236",
              "tail_entity_id": "T228"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R94",
              "head_entity_id": "T229",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R95",
              "head_entity_id": "T244",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R96",
              "head_entity_id": "T236",
              "tail_entity_id": "T229"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R97",
              "head_entity_id": "T230",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R98",
              "head_entity_id": "T232",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R99",
              "head_entity_id": "T244",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R100",
              "head_entity_id": "T236",
              "tail_entity_id": "T232"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R101",
              "head_entity_id": "T233",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R102",
              "head_entity_id": "T244",
              "tail_entity_id": "T233"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R103",
              "head_entity_id": "T236",
              "tail_entity_id": "T233"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R104",
              "head_entity_id": "T234",
              "tail_entity_id": "T242"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R105",
              "head_entity_id": "T239",
              "tail_entity_id": "T237"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R106",
              "head_entity_id": "T239",
              "tail_entity_id": "T238"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R107",
              "head_entity_id": "T239",
              "tail_entity_id": "T240"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R108",
              "head_entity_id": "T243",
              "tail_entity_id": "T242"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "19",
      "paragraph": "7.联合噻唑烷二酮类药物的疗效：对于严重IR，二甲双胍联合噻唑烷二酮类药物能更好地降低HbA1c，显著改善胰岛功能和IR，且有剂量依赖性趋势，但不良反应(体重增加、升高LDL-C)高于二甲双胍单用组；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著，故在IR严重，且排除两药的使用禁忌时，可考虑二甲双胍联合噻唑烷二酮类药物的治疗方案(Ⅰ级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "7.联合噻唑烷二酮类药物的疗效：对于严重IR，二甲双胍联合噻唑烷二酮类药物能更好地降低HbA1c，显著改善胰岛功能和IR，且有剂量依赖性趋势，但不良反应(体重增加、升高LDL-C)高于二甲双胍单用组；罗格列酮/二甲双胍的复合制剂与单用二甲双胍比较，复合制剂降低HbA1c和FPG更显著，故在IR严重，且排除两药的使用禁忌时，可考虑二甲双胍联合噻唑烷二酮类药物的治疗方案(Ⅰ级)。",
          "start_idx": 0,
          "end_idx": 189,
          "entities": [
            {
              "entity_id": "T246",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 27
            },
            {
              "entity_id": "T247",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 43,
              "end_idx": 48
            },
            {
              "entity_id": "T248",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 77,
              "end_idx": 81
            },
            {
              "entity_id": "T249",
              "entity": "升高LDL-C",
              "entity_type": "ADE",
              "start_idx": 82,
              "end_idx": 89
            },
            {
              "entity_id": "T250",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 37
            },
            {
              "entity_id": "T251",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 92,
              "end_idx": 96
            },
            {
              "entity_id": "T252",
              "entity": "罗格列酮/二甲双胍的复合制剂",
              "entity_type": "Drug",
              "start_idx": 100,
              "end_idx": 114
            },
            {
              "entity_id": "T253",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 117,
              "end_idx": 121
            },
            {
              "entity_id": "T254",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 58,
              "end_idx": 60
            },
            {
              "entity_id": "T255",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 20,
              "end_idx": 22
            },
            {
              "entity_id": "T256",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 12
            },
            {
              "entity_id": "T257",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 130,
              "end_idx": 135
            },
            {
              "entity_id": "T258",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 136,
              "end_idx": 139
            },
            {
              "entity_id": "T259",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 165,
              "end_idx": 169
            },
            {
              "entity_id": "T260",
              "entity": "噻唑烷二酮类药物",
              "entity_type": "Drug",
              "start_idx": 171,
              "end_idx": 179
            },
            {
              "entity_id": "T261",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 145,
              "end_idx": 147
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R109",
              "head_entity_id": "T248",
              "tail_entity_id": "T246"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R110",
              "head_entity_id": "T249",
              "tail_entity_id": "T246"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R111",
              "head_entity_id": "T248",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R112",
              "head_entity_id": "T248",
              "tail_entity_id": "T251"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R113",
              "head_entity_id": "T249",
              "tail_entity_id": "T250"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R114",
              "head_entity_id": "T249",
              "tail_entity_id": "T251"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "20",
      "paragraph": "8.联合格列奈类药物的疗效：格列奈类药物属于短效促胰岛素分泌剂，与二甲双胍联用具有协同作用。在新诊断的血糖水平较高(HbA1c水平接近11.0%)的T2DM患者中瑞格列奈和二甲双胍联合比单用瑞格列奈能更有效降低HbA1c，而低血糖发生率差异无统计学意义。那格列奈联用二甲双胍和格列齐特联用二甲双胍的降糖强度差异无统计学意义，但低血糖事件更少(Ⅰ级)。故在二甲双胍联合磺脲类且低血糖发生风险较高时，可考虑选用二甲双胍联合格列奈类药物。另有研究显示，在二甲双胍的基础上加用米格列奈，可进一步降低HbA1c、FPG和PPG，并提高达标率，而不良事件的发生率差异无统计学意义。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "8.联合格列奈类药物的疗效：格列奈类药物属于短效促胰岛素分泌剂，与二甲双胍联用具有协同作用。在新诊断的血糖水平较高(HbA1c水平接近11.0%)的T2DM患者中瑞格列奈和二甲双胍联合比单用瑞格列奈能更有效降低HbA1c，而低血糖发生率差异无统计学意义。那格列奈联用二甲双胍和格列齐特联用二甲双胍的降糖强度差异无统计学意义，但低血糖事件更少(Ⅰ级)。故在二甲双胍联合磺脲类且低血糖发生风险较高时，可考虑选用二甲双胍联合格列奈类药物。",
          "start_idx": 0,
          "end_idx": 216,
          "entities": [
            {
              "entity_id": "T262",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 10
            },
            {
              "entity_id": "T263",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 14,
              "end_idx": 20
            },
            {
              "entity_id": "T264",
              "entity": "短效促胰岛素分泌剂",
              "entity_type": "Drug",
              "start_idx": 22,
              "end_idx": 31
            },
            {
              "entity_id": "T265",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37
            },
            {
              "entity_id": "T266",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 51,
              "end_idx": 53
            },
            {
              "entity_id": "T267",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 58,
              "end_idx": 63
            },
            {
              "entity_id": "T268",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 78
            },
            {
              "entity_id": "T269",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 74,
              "end_idx": 76
            },
            {
              "entity_id": "T270",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 81,
              "end_idx": 85
            },
            {
              "entity_id": "T271",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 90
            },
            {
              "entity_id": "T272",
              "entity": "瑞格列奈",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T273",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 105,
              "end_idx": 110
            },
            {
              "entity_id": "T274",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 112,
              "end_idx": 115
            },
            {
              "entity_id": "T275",
              "entity": "那格列奈",
              "entity_type": "Drug",
              "start_idx": 127,
              "end_idx": 131
            },
            {
              "entity_id": "T276",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 133,
              "end_idx": 137
            },
            {
              "entity_id": "T277",
              "entity": "格列齐特",
              "entity_type": "Drug",
              "start_idx": 138,
              "end_idx": 142
            },
            {
              "entity_id": "T278",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 148
            },
            {
              "entity_id": "T279",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 163,
              "end_idx": 166
            },
            {
              "entity_id": "T280",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 177,
              "end_idx": 181
            },
            {
              "entity_id": "T281",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 183,
              "end_idx": 186
            },
            {
              "entity_id": "T282",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 187,
              "end_idx": 190
            },
            {
              "entity_id": "T283",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 207
            },
            {
              "entity_id": "T284",
              "entity": "格列奈类药物",
              "entity_type": "Drug",
              "start_idx": 209,
              "end_idx": 215
            },
            {
              "entity_id": "T290",
              "entity": "水平较高",
              "entity_type": "Test_Value",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T291",
              "entity": "接近11.0%",
              "entity_type": "Test_Value",
              "start_idx": 65,
              "end_idx": 72
            }
          ],
          "relations": [
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R115",
              "head_entity_id": "T266",
              "tail_entity_id": "T268"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R116",
              "head_entity_id": "T267",
              "tail_entity_id": "T268"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R117",
              "head_entity_id": "T269",
              "tail_entity_id": "T268"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R118",
              "head_entity_id": "T273",
              "tail_entity_id": "T268"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R119",
              "head_entity_id": "T272",
              "tail_entity_id": "T268"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R120",
              "head_entity_id": "T271",
              "tail_entity_id": "T268"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R121",
              "head_entity_id": "T270",
              "tail_entity_id": "T268"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R122",
              "head_entity_id": "T274",
              "tail_entity_id": "T270"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R123",
              "head_entity_id": "T274",
              "tail_entity_id": "T271"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R124",
              "head_entity_id": "T274",
              "tail_entity_id": "T272"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R125",
              "head_entity_id": "T279",
              "tail_entity_id": "T275"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R126",
              "head_entity_id": "T279",
              "tail_entity_id": "T276"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R127",
              "head_entity_id": "T279",
              "tail_entity_id": "T277"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R128",
              "head_entity_id": "T279",
              "tail_entity_id": "T278"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R129",
              "head_entity_id": "T282",
              "tail_entity_id": "T280"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R130",
              "head_entity_id": "T282",
              "tail_entity_id": "T281"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R131",
              "head_entity_id": "T282",
              "tail_entity_id": "T283"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R132",
              "head_entity_id": "T282",
              "tail_entity_id": "T284"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "另有研究显示，在二甲双胍的基础上加用米格列奈，可进一步降低HbA1c、FPG和PPG，并提高达标率，而不良事件的发生率差异无统计学意义。",
          "start_idx": 216,
          "end_idx": 284,
          "entities": [
            {
              "entity_id": "T285",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T286",
              "entity": "米格列奈",
              "entity_type": "Drug",
              "start_idx": 18,
              "end_idx": 22
            },
            {
              "entity_id": "T287",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 29,
              "end_idx": 34
            },
            {
              "entity_id": "T288",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 35,
              "end_idx": 38
            },
            {
              "entity_id": "T289",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 39,
              "end_idx": 42
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "21",
      "paragraph": "9.联合α糖苷酶抑制剂的疗效：二甲双胍与α糖苷酶抑制剂联合，可兼顺FPG和PPG，超重的T2DM患者在二甲双胍疗效不佳时，加用阿卡波糖能更好地控制HbA1c、FPG和体重。一项在中国T2DM人群中的对照研究显示，二甲双胍和阿卡波糖联用的降糖效果劣于二甲双胍和磺脲类联用。这两种药物都有一定的胃肠道不良反应，联合应用有可能增加胃肠不适。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "9.联合α糖苷酶抑制剂的疗效：二甲双胍与α糖苷酶抑制剂联合，可兼顺FPG和PPG，超重的T2DM患者在二甲双胍疗效不佳时，加用阿卡波糖能更好地控制HbA1c、FPG和体重。一项在中国T2DM人群中的对照研究显示，二甲双胍和阿卡波糖联用的降糖效果劣于二甲双胍和磺脲类联用。",
          "start_idx": 0,
          "end_idx": 135,
          "entities": [
            {
              "entity_id": "T292",
              "entity": "α糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 11
            },
            {
              "entity_id": "T293",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 43
            },
            {
              "entity_id": "T294",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T295",
              "entity": "α糖苷酶抑制剂",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 27
            },
            {
              "entity_id": "T296",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 33,
              "end_idx": 36
            },
            {
              "entity_id": "T297",
              "entity": "PPG",
              "entity_type": "Test_items",
              "start_idx": 37,
              "end_idx": 40
            },
            {
              "entity_id": "T298",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55
            },
            {
              "entity_id": "T299",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 63,
              "end_idx": 67
            },
            {
              "entity_id": "T300",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T301",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 44,
              "end_idx": 46
            },
            {
              "entity_id": "T302",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 78
            },
            {
              "entity_id": "T303",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 79,
              "end_idx": 82
            },
            {
              "entity_id": "T306",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 106,
              "end_idx": 110
            },
            {
              "entity_id": "T307",
              "entity": "阿卡波糖",
              "entity_type": "Drug",
              "start_idx": 111,
              "end_idx": 115
            },
            {
              "entity_id": "T308",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128
            },
            {
              "entity_id": "T309",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 132
            },
            {
              "entity_id": "T310",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 95
            },
            {
              "entity_id": "T311",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 91,
              "end_idx": 93
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R133",
              "head_entity_id": "T298",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R134",
              "head_entity_id": "T299",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R135",
              "head_entity_id": "T302",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R136",
              "head_entity_id": "T303",
              "tail_entity_id": "T293"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R137",
              "head_entity_id": "T298",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R138",
              "head_entity_id": "T299",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R139",
              "head_entity_id": "T301",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R140",
              "head_entity_id": "T303",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R141",
              "head_entity_id": "T302",
              "tail_entity_id": "T300"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R142",
              "head_entity_id": "T306",
              "tail_entity_id": "T310"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R143",
              "head_entity_id": "T307",
              "tail_entity_id": "T310"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R144",
              "head_entity_id": "T308",
              "tail_entity_id": "T310"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R145",
              "head_entity_id": "T309",
              "tail_entity_id": "T310"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R146",
              "head_entity_id": "T311",
              "tail_entity_id": "T310"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "这两种药物都有一定的胃肠道不良反应，联合应用有可能增加胃肠不适。",
          "start_idx": 135,
          "end_idx": 167,
          "entities": [
            {
              "entity_id": "T304",
              "entity": "胃肠道不良反应",
              "entity_type": "ADE",
              "start_idx": 10,
              "end_idx": 17
            },
            {
              "entity_id": "T305",
              "entity": "胃肠不适",
              "entity_type": "ADE",
              "start_idx": 27,
              "end_idx": 31
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "22",
      "paragraph": "10.联合DPP-4抑制剂的疗效：二甲双胍联合DPP-4抑制剂在降低FPG、HbA1c、体重的幅度均强于两药单用，但是对心血管危险因素、低血糖、胃肠道作用差异无统计学意义，二甲双胍联合DPP-4抑制剂的疗效与二甲双胍联合磺脲类药物的疗效相当，但体重增加和低血糖发生的风险低于二甲双胍联合磺脲类药物，由于DPP-4抑制剂上市时间较短，关于二甲双胍和DPP-4抑制剂的联合用药的疗效和安全性，还需要更多的研究验证。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "10.联合DPP-4抑制剂的疗效：二甲双胍联合DPP-4抑制剂在降低FPG、HbA1c、体重的幅度均强于两药单用，但是对心血管危险因素、低血糖、胃肠道作用差异无统计学意义，二甲双胍联合DPP-4抑制剂的疗效与二甲双胍联合磺脲类药物的疗效相当，但体重增加和低血糖发生的风险低于二甲双胍联合磺脲类药物，由于DPP-4抑制剂上市时间较短，关于二甲双胍和DPP-4抑制剂的联合用药的疗效和安全性，还需要更多的研究验证。",
          "start_idx": 0,
          "end_idx": 205,
          "entities": [
            {
              "entity_id": "T312",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 13
            },
            {
              "entity_id": "T313",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 17,
              "end_idx": 21
            },
            {
              "entity_id": "T314",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 23,
              "end_idx": 31
            },
            {
              "entity_id": "T315",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 34,
              "end_idx": 37
            },
            {
              "entity_id": "T316",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 38,
              "end_idx": 43
            },
            {
              "entity_id": "T317",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 68,
              "end_idx": 71
            },
            {
              "entity_id": "T318",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 90
            },
            {
              "entity_id": "T319",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 92,
              "end_idx": 100
            },
            {
              "entity_id": "T320",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108
            },
            {
              "entity_id": "T321",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 110,
              "end_idx": 115
            },
            {
              "entity_id": "T322",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 141
            },
            {
              "entity_id": "T323",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 148
            },
            {
              "entity_id": "T324",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 151,
              "end_idx": 159
            },
            {
              "entity_id": "T325",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 168,
              "end_idx": 172
            },
            {
              "entity_id": "T326",
              "entity": "DPP-4抑制剂",
              "entity_type": "Drug",
              "start_idx": 173,
              "end_idx": 181
            },
            {
              "entity_id": "T327",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 127,
              "end_idx": 130
            },
            {
              "entity_id": "T328",
              "entity": "胃肠道作用",
              "entity_type": "ADE",
              "start_idx": 72,
              "end_idx": 77
            },
            {
              "entity_id": "T329",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 122,
              "end_idx": 126
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R147",
              "head_entity_id": "T317",
              "tail_entity_id": "T313"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R148",
              "head_entity_id": "T328",
              "tail_entity_id": "T313"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R149",
              "head_entity_id": "T317",
              "tail_entity_id": "T314"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R150",
              "head_entity_id": "T328",
              "tail_entity_id": "T314"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R151",
              "head_entity_id": "T329",
              "tail_entity_id": "T318"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R152",
              "head_entity_id": "T327",
              "tail_entity_id": "T318"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R153",
              "head_entity_id": "T329",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R154",
              "head_entity_id": "T327",
              "tail_entity_id": "T319"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R155",
              "head_entity_id": "T329",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R156",
              "head_entity_id": "T327",
              "tail_entity_id": "T320"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R157",
              "head_entity_id": "T329",
              "tail_entity_id": "T321"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R158",
              "head_entity_id": "T327",
              "tail_entity_id": "T321"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R159",
              "head_entity_id": "T329",
              "tail_entity_id": "T322"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R160",
              "head_entity_id": "T327",
              "tail_entity_id": "T322"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R161",
              "head_entity_id": "T329",
              "tail_entity_id": "T323"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R162",
              "head_entity_id": "T327",
              "tail_entity_id": "T323"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "23",
      "paragraph": "11.联合GLP-1受体激动剂的疗效：目前中国临床应用的GLP-1受体激动剂主要包括利拉鲁肽和艾塞那肽。在二甲双胍治疗基础上加用GLP-1受体激动剂，可进一步降低FPG、HbA1c，血糖达标率更高：改善胰岛素β细胞功能：改善IR，降低体重和SBP，无严重低血糖事件(Ⅰ级)。在我国T2DM人群中开展的随机分组、对照性研究显示，利拉鲁肽联合二甲双胍与格列美脲联合二甲双胍相比降糖疗效相当，体重和血压显著降低，低血糖发生风险显著减少。但患者对利拉鲁肽联合二甲双胍治疗所导致的不良反应的耐受性更差。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "11.联合GLP-1受体激动剂的疗效：目前中国临床应用的GLP-1受体激动剂主要包括利拉鲁肽和艾塞那肽。在二甲双胍治疗基础上加用GLP-1受体激动剂，可进一步降低FPG、HbA1c，血糖达标率更高：改善胰岛素β细胞功能：改善IR，降低体重和SBP，无严重低血糖事件(Ⅰ级)。在我国T2DM人群中开展的随机分组、对照性研究显示，利拉鲁肽联合二甲双胍与格列美脲联合二甲双胍相比降糖疗效相当，体重和血压显著降低，低血糖发生风险显著减少。",
          "start_idx": 0,
          "end_idx": 215,
          "entities": [
            {
              "entity_id": "T330",
              "entity": "艾塞那肽",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51
            },
            {
              "entity_id": "T331",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T332",
              "entity": "FPG",
              "entity_type": "Test_items",
              "start_idx": 81,
              "end_idx": 84
            },
            {
              "entity_id": "T333",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 85,
              "end_idx": 90
            },
            {
              "entity_id": "T334",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 91,
              "end_idx": 93
            },
            {
              "entity_id": "T335",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 127,
              "end_idx": 130
            },
            {
              "entity_id": "T336",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 140,
              "end_idx": 144
            },
            {
              "entity_id": "T337",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 140,
              "end_idx": 142
            },
            {
              "entity_id": "T338",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 167
            },
            {
              "entity_id": "T339",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 42,
              "end_idx": 46
            },
            {
              "entity_id": "T340",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 169,
              "end_idx": 173
            },
            {
              "entity_id": "T341",
              "entity": "格列美脲",
              "entity_type": "Drug",
              "start_idx": 174,
              "end_idx": 178
            },
            {
              "entity_id": "T342",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 180,
              "end_idx": 184
            },
            {
              "entity_id": "T343",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 203,
              "end_idx": 206
            },
            {
              "entity_id": "T346",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 38
            },
            {
              "entity_id": "T347",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 74
            },
            {
              "entity_id": "T348",
              "entity": "GLP-1受体激动剂",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 15
            },
            {
              "entity_id": "T349",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 112,
              "end_idx": 114
            },
            {
              "entity_id": "T350",
              "entity": "达标率更高",
              "entity_type": "Test_Value",
              "start_idx": 93,
              "end_idx": 98
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R163",
              "head_entity_id": "T335",
              "tail_entity_id": "T331"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R164",
              "head_entity_id": "T335",
              "tail_entity_id": "T347"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R165",
              "head_entity_id": "T337",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R166",
              "head_entity_id": "T338",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R167",
              "head_entity_id": "T340",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R168",
              "head_entity_id": "T341",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R169",
              "head_entity_id": "T342",
              "tail_entity_id": "T336"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R170",
              "head_entity_id": "T343",
              "tail_entity_id": "T338"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R171",
              "head_entity_id": "T343",
              "tail_entity_id": "T340"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R172",
              "head_entity_id": "T343",
              "tail_entity_id": "T341"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R173",
              "head_entity_id": "T343",
              "tail_entity_id": "T342"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "但患者对利拉鲁肽联合二甲双胍治疗所导致的不良反应的耐受性更差。",
          "start_idx": 215,
          "end_idx": 246,
          "entities": [
            {
              "entity_id": "T344",
              "entity": "利拉鲁肽",
              "entity_type": "Drug",
              "start_idx": 4,
              "end_idx": 8
            },
            {
              "entity_id": "T345",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "24",
      "paragraph": "12.联合胰岛素的疗效：二甲双胍可增强肝脏和肌肉组织的IR，因此在开始胰岛素治疗的同时应该继续维持二甲双胍治疗。与胰岛素单药治疗相比，二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量，还可减少使用胰岛素之后出现的体重增加(Ⅰ级)，一项随机对照研究人组了接受胰岛素单药治疗但HbA1c≥7.0%的T2DM患者，受试者随机接受胰岛素单药(n=31)或胰岛素联合二甲双胍(n=27)治疗4个月。结果显示，二甲双胍联合胰岛素治疗，在保证相同降精疗效的同时，可减少胰岛素用量，从而降低低血糖的发生风险。Yki-Jarvinen等将96例接受磺脲类药物治疗血糖控制不佳的T2DM患者，随机分为睡前胰岛素+二甲双胍+安慰剂组、睡前胰岛素+格列本脲+安慰剂组、睡前胰岛素+二甲双胍+格列本脲和睡前胰岛素+清晨胰岛素组。治疗1年后，睡前胰岛素+二甲双胍组体重无明显变化，而其他组的体重均有所增加，且与其他组相比，睡前胰岛素+二甲双胍组HbA1c降幅最大，每日胰岛素用量最少，低血糖的发生率最低。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "12.联合胰岛素的疗效：二甲双胍可增强肝脏和肌肉组织的IR，因此在开始胰岛素治疗的同时应该继续维持二甲双胍治疗。与胰岛素单药治疗相比，二甲双胍联合胰岛素可进一步降低HbA1c，减少胰岛素用量，还可减少使用胰岛素之后出现的体重增加(Ⅰ级)，一项随机对照研究人组了接受胰岛素单药治疗但HbA1c≥7.0%的T2DM患者，受试者随机接受胰岛素单药(n=31)或胰岛素联合二甲双胍(n=27)治疗4个月。结果显示，二甲双胍联合胰岛素治疗，在保证相同降精疗效的同时，可减少胰岛素用量，从而降低低血糖的发生风险。Yki-Jarvinen等将96例接受磺脲类药物治疗血糖控制不佳的T2DM患者，随机分为睡前胰岛素+二甲双胍+安慰剂组、睡前胰岛素+格列本脲+安慰剂组、睡前胰岛素+二甲双胍+格列本脲和睡前胰岛素+清晨胰岛素组。治疗1年后，睡前胰岛素+二甲双胍组体重无明显变化，而其他组的体重均有所增加，且与其他组相比，睡前胰岛素+二甲双胍组HbA1c降幅最大，每日胰岛素用量最少，低血糖的发生率最低。",
          "start_idx": 0,
          "end_idx": 442,
          "entities": [
            {
              "entity_id": "T351",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 8
            },
            {
              "entity_id": "T352",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16
            },
            {
              "entity_id": "T353",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 38
            },
            {
              "entity_id": "T354",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T355",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 57,
              "end_idx": 60
            },
            {
              "entity_id": "T356",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 67,
              "end_idx": 71
            },
            {
              "entity_id": "T357",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 73,
              "end_idx": 76
            },
            {
              "entity_id": "T358",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 82,
              "end_idx": 87
            },
            {
              "entity_id": "T359",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 93
            },
            {
              "entity_id": "T360",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 102,
              "end_idx": 105
            },
            {
              "entity_id": "T361",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 110,
              "end_idx": 114
            },
            {
              "entity_id": "T362",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 151,
              "end_idx": 155
            },
            {
              "entity_id": "T363",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 151,
              "end_idx": 153
            },
            {
              "entity_id": "T364",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 132,
              "end_idx": 135
            },
            {
              "entity_id": "T365",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 140,
              "end_idx": 145
            },
            {
              "entity_id": "T366",
              "entity": "≥7.0%",
              "entity_type": "Test_Value",
              "start_idx": 145,
              "end_idx": 150
            },
            {
              "entity_id": "T367",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 165,
              "end_idx": 168
            },
            {
              "entity_id": "T368",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 177,
              "end_idx": 180
            },
            {
              "entity_id": "T369",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 186
            },
            {
              "entity_id": "T370",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 203,
              "end_idx": 207
            },
            {
              "entity_id": "T371",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 209,
              "end_idx": 212
            },
            {
              "entity_id": "T372",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 231,
              "end_idx": 234
            },
            {
              "entity_id": "T373",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 241,
              "end_idx": 244
            },
            {
              "entity_id": "T374",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 283,
              "end_idx": 287
            },
            {
              "entity_id": "T375",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 283,
              "end_idx": 285
            },
            {
              "entity_id": "T376",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 276,
              "end_idx": 278
            },
            {
              "entity_id": "T377",
              "entity": "磺脲类药物",
              "entity_type": "Drug",
              "start_idx": 269,
              "end_idx": 274
            },
            {
              "entity_id": "T378",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 296,
              "end_idx": 299
            },
            {
              "entity_id": "T379",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 300,
              "end_idx": 304
            },
            {
              "entity_id": "T380",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 312,
              "end_idx": 315
            },
            {
              "entity_id": "T381",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 316,
              "end_idx": 320
            },
            {
              "entity_id": "T382",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 328,
              "end_idx": 331
            },
            {
              "entity_id": "T383",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 332,
              "end_idx": 336
            },
            {
              "entity_id": "T384",
              "entity": "格列本脲",
              "entity_type": "Drug",
              "start_idx": 337,
              "end_idx": 341
            },
            {
              "entity_id": "T385",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 344,
              "end_idx": 347
            },
            {
              "entity_id": "T386",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 350,
              "end_idx": 353
            },
            {
              "entity_id": "T387",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 27,
              "end_idx": 29
            },
            {
              "entity_id": "T388",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 363,
              "end_idx": 366
            },
            {
              "entity_id": "T389",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 367,
              "end_idx": 371
            },
            {
              "entity_id": "T390",
              "entity": "体重均有所增加",
              "entity_type": "ADE",
              "start_idx": 385,
              "end_idx": 392
            },
            {
              "entity_id": "T391",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 403,
              "end_idx": 406
            },
            {
              "entity_id": "T392",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 407,
              "end_idx": 411
            },
            {
              "entity_id": "T393",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 412,
              "end_idx": 417
            },
            {
              "entity_id": "T394",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 424,
              "end_idx": 427
            },
            {
              "entity_id": "T395",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 432,
              "end_idx": 435
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R174",
              "head_entity_id": "T361",
              "tail_entity_id": "T360"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R175",
              "head_entity_id": "T363",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R176",
              "head_entity_id": "T364",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R177",
              "head_entity_id": "T367",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R178",
              "head_entity_id": "T368",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R179",
              "head_entity_id": "T369",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R180",
              "head_entity_id": "T365",
              "tail_entity_id": "T362"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R181",
              "head_entity_id": "T373",
              "tail_entity_id": "T370"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R182",
              "head_entity_id": "T373",
              "tail_entity_id": "T371"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R183",
              "head_entity_id": "T373",
              "tail_entity_id": "T372"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R184",
              "head_entity_id": "T375",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R185",
              "head_entity_id": "T376",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R186",
              "head_entity_id": "T377",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R187",
              "head_entity_id": "T378",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R188",
              "head_entity_id": "T379",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R189",
              "head_entity_id": "T380",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R190",
              "head_entity_id": "T381",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R191",
              "head_entity_id": "T382",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R192",
              "head_entity_id": "T383",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R193",
              "head_entity_id": "T384",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R194",
              "head_entity_id": "T385",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R195",
              "head_entity_id": "T386",
              "tail_entity_id": "T374"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R196",
              "head_entity_id": "T395",
              "tail_entity_id": "T391"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R197",
              "head_entity_id": "T395",
              "tail_entity_id": "T392"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R198",
              "head_entity_id": "T395",
              "tail_entity_id": "T394"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "25",
      "paragraph": "13.应尽早足量使用以维持更长的达标时间：在500~2000mg剂量范围，二甲双胍疗效呈现剂量依赖效应，且相比其他降糖药物，二甲双胍具有更好的成本效益比(Ⅰ级)。ADOPT研究显示，在新诊断的T2DM患者中，二甲双胍(2000mg/d)单药治疗可以在4年内使受试者平均HbA1c水平维持在7%以下。在一项长达104周的对照临床研究中，与西格列汀(100mg/d)单药治疗相比，二甲双胍(2000mg/d)单药治疗使受试者平均HbA1c水平维持在7%以下的时间增加了约24周。因此，在患者可以耐受的情况下，使用单药最佳剂量(2000mg/d)的二甲双胍治疗不但可以使血糖控制尽早达标，且可使血糖得到更长时间的良好控制，如果出现可耐受的不良反应时，可适当减量；如果不能耐受，建议尽早更换其他降糖药。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "13.应尽早足量使用以维持更长的达标时间：在500~2000mg剂量范围，二甲双胍疗效呈现剂量依赖效应，且相比其他降糖药物，二甲双胍具有更好的成本效益比(Ⅰ级)。ADOPT研究显示，在新诊断的T2DM患者中，二甲双胍(2000mg/d)单药治疗可以在4年内使受试者平均HbA1c水平维持在7%以下。",
          "start_idx": 0,
          "end_idx": 149,
          "entities": [
            {
              "entity_id": "T396",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T397",
              "entity": "500~2000mg",
              "entity_type": "Amount",
              "start_idx": 22,
              "end_idx": 32
            },
            {
              "entity_id": "T398",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 62,
              "end_idx": 66
            },
            {
              "entity_id": "T399",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 96,
              "end_idx": 100
            },
            {
              "entity_id": "T400",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 96,
              "end_idx": 98
            },
            {
              "entity_id": "T401",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 104,
              "end_idx": 108
            },
            {
              "entity_id": "T402",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 109,
              "end_idx": 117
            },
            {
              "entity_id": "T403",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 134,
              "end_idx": 139
            },
            {
              "entity_id": "T414",
              "entity": "7%以下",
              "entity_type": "Test_Value",
              "start_idx": 144,
              "end_idx": 148
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R199",
              "head_entity_id": "T397",
              "tail_entity_id": "T396"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R200",
              "head_entity_id": "T400",
              "tail_entity_id": "T399"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R201",
              "head_entity_id": "T401",
              "tail_entity_id": "T399"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R202",
              "head_entity_id": "T403",
              "tail_entity_id": "T399"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R203",
              "head_entity_id": "T402",
              "tail_entity_id": "T401"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "在一项长达104周的对照临床研究中，与西格列汀(100mg/d)单药治疗相比，二甲双胍(2000mg/d)单药治疗使受试者平均HbA1c水平维持在7%以下的时间增加了约24周。",
          "start_idx": 149,
          "end_idx": 237,
          "entities": [
            {
              "entity_id": "T404",
              "entity": "西格列汀",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23
            },
            {
              "entity_id": "T405",
              "entity": "100mg/d",
              "entity_type": "Amount",
              "start_idx": 24,
              "end_idx": 31
            },
            {
              "entity_id": "T406",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 39,
              "end_idx": 43
            },
            {
              "entity_id": "T407",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 44,
              "end_idx": 52
            },
            {
              "entity_id": "T408",
              "entity": "HbA1c",
              "entity_type": "Test_items",
              "start_idx": 63,
              "end_idx": 68
            },
            {
              "entity_id": "T413",
              "entity": "7%以下",
              "entity_type": "Test_Value",
              "start_idx": 73,
              "end_idx": 77
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R204",
              "head_entity_id": "T405",
              "tail_entity_id": "T404"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R205",
              "head_entity_id": "T407",
              "tail_entity_id": "T406"
            }
          ]
        },
        {
          "sentence_id": "2",
          "sentence": "因此，在患者可以耐受的情况下，使用单药最佳剂量(2000mg/d)的二甲双胍治疗不但可以使血糖控制尽早达标，且可使血糖得到更长时间的良好控制，如果出现可耐受的不良反应时，可适当减量；如果不能耐受，建议尽早更换其他降糖药。",
          "start_idx": 237,
          "end_idx": 347,
          "entities": [
            {
              "entity_id": "T409",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 34,
              "end_idx": 38
            },
            {
              "entity_id": "T410",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 24,
              "end_idx": 32
            },
            {
              "entity_id": "T411",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 59
            },
            {
              "entity_id": "T412",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 45,
              "end_idx": 47
            }
          ],
          "relations": [
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R206",
              "head_entity_id": "T410",
              "tail_entity_id": "T409"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "26",
      "paragraph": "14.用于正在接受胰岛素治疗的T1DM患者：对于T1DM患者可联用二甲双胍。临床研究发现其不仅能减少胰岛素用量，还可进一步降低血脂水平(与降低血糖无关)，尤其是LDL-C；对于单用胰岛索治疗血糖控不佳的患者，如果联合二甲双胍，可降低胰岛素用量10%，减少使用胰岛素所带来的体重过度增加。中国T1DM诊治指南也支持T1DM在使用胰岛素治疗的前提下联用二甲双胍。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "14.用于正在接受胰岛素治疗的T1DM患者：对于T1DM患者可联用二甲双胍。临床研究发现其不仅能减少胰岛素用量，还可进一步降低血脂水平(与降低血糖无关)，尤其是LDL-C；对于单用胰岛索治疗血糖控不佳的患者，如果联合二甲双胍，可降低胰岛素用量10%，减少使用胰岛素所带来的体重过度增加。中国T1DM诊治指南也支持T1DM在使用胰岛素治疗的前提下联用二甲双胍。",
          "start_idx": 0,
          "end_idx": 179,
          "entities": [
            {
              "entity_id": "T415",
              "entity": "T1DM",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T416",
              "entity": "T1",
              "entity_type": "Class",
              "start_idx": 15,
              "end_idx": 17
            },
            {
              "entity_id": "T417",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 12
            },
            {
              "entity_id": "T418",
              "entity": "T1DM",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 28
            },
            {
              "entity_id": "T419",
              "entity": "T1",
              "entity_type": "Class",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T420",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37
            },
            {
              "entity_id": "T421",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 53
            },
            {
              "entity_id": "T422",
              "entity": "血脂",
              "entity_type": "Test",
              "start_idx": 63,
              "end_idx": 65
            },
            {
              "entity_id": "T423",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 71,
              "end_idx": 73
            },
            {
              "entity_id": "T424",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 85
            },
            {
              "entity_id": "T425",
              "entity": "胰岛索",
              "entity_type": "Drug",
              "start_idx": 90,
              "end_idx": 93
            },
            {
              "entity_id": "T426",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 95,
              "end_idx": 97
            },
            {
              "entity_id": "T427",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 108,
              "end_idx": 112
            },
            {
              "entity_id": "T428",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 116,
              "end_idx": 119
            },
            {
              "entity_id": "T429",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 129,
              "end_idx": 132
            },
            {
              "entity_id": "T430",
              "entity": "体重过度增加",
              "entity_type": "ADE",
              "start_idx": 136,
              "end_idx": 142
            },
            {
              "entity_id": "T431",
              "entity": "T1DM",
              "entity_type": "Disease",
              "start_idx": 145,
              "end_idx": 149
            },
            {
              "entity_id": "T432",
              "entity": "T1",
              "entity_type": "Class",
              "start_idx": 145,
              "end_idx": 147
            },
            {
              "entity_id": "T433",
              "entity": "T1DM",
              "entity_type": "Disease",
              "start_idx": 156,
              "end_idx": 160
            },
            {
              "entity_id": "T434",
              "entity": "T1",
              "entity_type": "Class",
              "start_idx": 156,
              "end_idx": 158
            },
            {
              "entity_id": "T435",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 166
            },
            {
              "entity_id": "T436",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 174,
              "end_idx": 178
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R207",
              "head_entity_id": "T416",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R208",
              "head_entity_id": "T417",
              "tail_entity_id": "T415"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R209",
              "head_entity_id": "T419",
              "tail_entity_id": "T418"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R210",
              "head_entity_id": "T420",
              "tail_entity_id": "T418"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R211",
              "head_entity_id": "T421",
              "tail_entity_id": "T418"
            },
            {
              "relation_type": "Test_Disease",
              "relation_id": "R212",
              "head_entity_id": "T422",
              "tail_entity_id": "T418"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R213",
              "head_entity_id": "T423",
              "tail_entity_id": "T418"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R214",
              "head_entity_id": "T424",
              "tail_entity_id": "T418"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R215",
              "head_entity_id": "T430",
              "tail_entity_id": "T429"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R216",
              "head_entity_id": "T432",
              "tail_entity_id": "T431"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R217",
              "head_entity_id": "T434",
              "tail_entity_id": "T433"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R218",
              "head_entity_id": "T435",
              "tail_entity_id": "T433"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R219",
              "head_entity_id": "T436",
              "tail_entity_id": "T433"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "27",
      "paragraph": "15.减重效果：二甲双胍具有控制体重的作用。研究表明，新诊断T2DM患者二甲双胍单药治疗16周，可使正常(BMI18.5~23.9kg/m2)、超重(BMI24.0~27.9kg/m2)、肥胖(BMI≥28.0kg/m2)患者的体重分别下降(可能包含部分安慰剂效应)1.47、2.81及2.92kg(Ⅰ级)，磺脲类、格列酮类和胰岛素治疗伴有体重增加，以二甲双胍为基础的联合治疗减轻上述药物对体重增加的影响。HOME研究证实，以二甲双胍为基础联合胰岛素治疗，体重少增加2.28~3.85kg。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "15.减重效果：二甲双胍具有控制体重的作用。研究表明，新诊断T2DM患者二甲双胍单药治疗16周，可使正常(BMI18.5~23.9kg/m2)、超重(BMI24.0~27.9kg/m2)、肥胖(BMI≥28.0kg/m2)患者的体重分别下降(可能包含部分安慰剂效应)1.47、2.81及2.92kg(Ⅰ级)，磺脲类、格列酮类和胰岛素治疗伴有体重增加，以二甲双胍为基础的联合治疗减轻上述药物对体重增加的影响。",
          "start_idx": 0,
          "end_idx": 203,
          "entities": [
            {
              "entity_id": "T437",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T438",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 34
            },
            {
              "entity_id": "T439",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 32
            },
            {
              "entity_id": "T440",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 40
            },
            {
              "entity_id": "T441",
              "entity": "超重",
              "entity_type": "Disease",
              "start_idx": 72,
              "end_idx": 74
            },
            {
              "entity_id": "T442",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 94,
              "end_idx": 96
            },
            {
              "entity_id": "T443",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 170,
              "end_idx": 174
            },
            {
              "entity_id": "T444",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 154,
              "end_idx": 157
            },
            {
              "entity_id": "T445",
              "entity": "格列酮类",
              "entity_type": "Drug",
              "start_idx": 158,
              "end_idx": 162
            },
            {
              "entity_id": "T446",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 166
            },
            {
              "entity_id": "T447",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 176,
              "end_idx": 180
            },
            {
              "entity_id": "T450",
              "entity": "体重增加",
              "entity_type": "ADE",
              "start_idx": 195,
              "end_idx": 199
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R220",
              "head_entity_id": "T439",
              "tail_entity_id": "T438"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R221",
              "head_entity_id": "T440",
              "tail_entity_id": "T438"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R222",
              "head_entity_id": "T443",
              "tail_entity_id": "T444"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R223",
              "head_entity_id": "T443",
              "tail_entity_id": "T445"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R224",
              "head_entity_id": "T443",
              "tail_entity_id": "T446"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "HOME研究证实，以二甲双胍为基础联合胰岛素治疗，体重少增加2.28~3.85kg。",
          "start_idx": 203,
          "end_idx": 245,
          "entities": [
            {
              "entity_id": "T448",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T449",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 22
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "28",
      "paragraph": "四、特殊人群用药",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "四、特殊人群用药",
          "start_idx": 0,
          "end_idx": 8,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "29",
      "paragraph": "1.心力衰竭患者使用注意事项：需要药物治疗的充血性心力衰竭(CHF)是二甲双胍使用的禁忌证，但回顾性研究显示，二甲双胍本身不会导致心力衰竭，也不会对心力衰竭患者造成不良影响。2014年ADA糖尿病指南也指出，如果肾功能正常，二甲双胍可用于病情稳定的CHF患者(Ⅴ级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.心力衰竭患者使用注意事项：需要药物治疗的充血性心力衰竭(CHF)是二甲双胍使用的禁忌证，但回顾性研究显示，二甲双胍本身不会导致心力衰竭，也不会对心力衰竭患者造成不良影响。2014年ADA糖尿病指南也指出，如果肾功能正常，二甲双胍可用于病情稳定的CHF患者(Ⅴ级)。",
          "start_idx": 0,
          "end_idx": 134,
          "entities": [
            {
              "entity_id": "T451",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T452",
              "entity": "充血性心力衰竭(CHF)",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 34
            },
            {
              "entity_id": "T453",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 35,
              "end_idx": 39
            },
            {
              "entity_id": "T454",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 55,
              "end_idx": 59
            },
            {
              "entity_id": "T455",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T456",
              "entity": "心力衰竭",
              "entity_type": "Disease",
              "start_idx": 74,
              "end_idx": 78
            },
            {
              "entity_id": "T457",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 98
            },
            {
              "entity_id": "T458",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 112,
              "end_idx": 116
            },
            {
              "entity_id": "T459",
              "entity": "CHF",
              "entity_type": "Disease",
              "start_idx": 124,
              "end_idx": 127
            },
            {
              "entity_id": "T460",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            },
            {
              "entity_id": "T461",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 25,
              "end_idx": 26
            },
            {
              "entity_id": "T462",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 65,
              "end_idx": 66
            },
            {
              "entity_id": "T463",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 74,
              "end_idx": 75
            },
            {
              "entity_id": "T464",
              "entity": "充血性",
              "entity_type": "Class",
              "start_idx": 22,
              "end_idx": 25
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R225",
              "head_entity_id": "T460",
              "tail_entity_id": "T451"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R226",
              "head_entity_id": "T461",
              "tail_entity_id": "T452"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R227",
              "head_entity_id": "T464",
              "tail_entity_id": "T452"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R228",
              "head_entity_id": "T462",
              "tail_entity_id": "T455"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R229",
              "head_entity_id": "T463",
              "tail_entity_id": "T456"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R230",
              "head_entity_id": "T458",
              "tail_entity_id": "T457"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R231",
              "head_entity_id": "T458",
              "tail_entity_id": "T459"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "30",
      "paragraph": "2.65岁以上老年患者使用注意事项：2013年IDF老年糖尿病指南和中国老年糖尿病诊疗措施专家共识都把二甲双胍作为一线首选用药，对二甲双胍的使用没有具体年龄限制。老年糖尿病患者合理应用二甲双胍治疗可以达到良好的降糖效果，较少的低血糖风险对老年人有一定益处，但需要定期监测肾功能(3~6个月检查1次)。80岁以上患者[eGFR<45ml/(min·1.73m2)除外]，如掌握好适应证，从小剂量起始，在合理监测条件下，应用二甲双胍仍可取得良好的效果(Ⅰ级)。因此，年龄并非二甲双胍治疗的禁忌，但需要监测肾功能。老年患者的eGFR在45~60ml/(min·1.73ml2)者，应减少剂量，如果eGFR<45ml/(min·1.73m2)则不能使用]。适合我国CKD患者的eGFR评估公式为：cG FR[ml/(min·1.73m2)]=175×Scr-1.234(mg/dI)×年龄-0.179(女性X0.79)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.65岁以上老年患者使用注意事项：2013年IDF老年糖尿病指南和中国老年糖尿病诊疗措施专家共识都把二甲双胍作为一线首选用药，对二甲双胍的使用没有具体年龄限制。老年糖尿病患者合理应用二甲双胍治疗可以达到良好的降糖效果，较少的低血糖风险对老年人有一定益处，但需要定期监测肾功能(3~6个月检查1次)。",
          "start_idx": 0,
          "end_idx": 150,
          "entities": [
            {
              "entity_id": "T465",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 31
            },
            {
              "entity_id": "T466",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 38,
              "end_idx": 41
            },
            {
              "entity_id": "T467",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55
            },
            {
              "entity_id": "T468",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 65,
              "end_idx": 69
            },
            {
              "entity_id": "T469",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 86
            },
            {
              "entity_id": "T470",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 92,
              "end_idx": 96
            },
            {
              "entity_id": "T471",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 113,
              "end_idx": 116
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R232",
              "head_entity_id": "T467",
              "tail_entity_id": "T465"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R233",
              "head_entity_id": "T467",
              "tail_entity_id": "T466"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R234",
              "head_entity_id": "T470",
              "tail_entity_id": "T469"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R235",
              "head_entity_id": "T471",
              "tail_entity_id": "T470"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "80岁以上患者[eGFR<45ml/(min·1.73m2)除外]，如掌握好适应证，从小剂量起始，在合理监测条件下，应用二甲双胍仍可取得良好的效果(Ⅰ级)。",
          "start_idx": 150,
          "end_idx": 228,
          "entities": [
            {
              "entity_id": "T472",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 60,
              "end_idx": 64
            },
            {
              "entity_id": "T474",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T475",
              "entity": "<45ml/(min·1.73m2",
              "entity_type": "Test_Value",
              "start_idx": 12,
              "end_idx": 29
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "因此，年龄并非二甲双胍治疗的禁忌，但需要监测肾功能。",
          "start_idx": 228,
          "end_idx": 254,
          "entities": [
            {
              "entity_id": "T473",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "3",
          "sentence": "老年患者的eGFR在45~60ml/(min·1.73ml2)者，应减少剂量，如果eGFR<45ml/(min·1.73m2)则不能使用]。",
          "start_idx": 254,
          "end_idx": 324,
          "entities": [
            {
              "entity_id": "T476",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 5,
              "end_idx": 9
            },
            {
              "entity_id": "T477",
              "entity": "45~60ml/(min·1.73ml2)",
              "entity_type": "Test_Value",
              "start_idx": 10,
              "end_idx": 31
            },
            {
              "entity_id": "T478",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 41,
              "end_idx": 45
            },
            {
              "entity_id": "T479",
              "entity": "<45ml/(min·1.73m2)",
              "entity_type": "Test_Value",
              "start_idx": 45,
              "end_idx": 63
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "4",
          "sentence": "适合我国CKD患者的eGFR评估公式为：cG FR[ml/(min·1.73m2)]=175×Scr-1.234(mg/dI)×年龄-0.179(女性X0.79)。",
          "start_idx": 324,
          "end_idx": 406,
          "entities": [
            {
              "entity_id": "T480",
              "entity": "CKD",
              "entity_type": "Disease",
              "start_idx": 4,
              "end_idx": 7
            },
            {
              "entity_id": "T481",
              "entity": "cG FR",
              "entity_type": "Test_items",
              "start_idx": 20,
              "end_idx": 25
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "31",
      "paragraph": "3.儿童和青少年糖尿病及糖尿病前期患儿使用注意事项：无需以胰岛素作为起始治疗的10岁及以上T2DM患儿，应立即开始给予生活方式干预，不达标者以二甲双胍作为起始治疗药物。10岁及以上的糖尿病前期(IFG或lGT)患儿经3个月有效的生活方式干预(饮食控制、150min/周运动，减轻体重5%~10%)后，代谢异常指标仍无法逆转，建议使用二甲双胍治疗，起始剂量500mg，3次/d，最大剂量2000mg/d(V级)。二甲双胍可用于10岁及以上的T2DM的儿童或青少年，且最高剂量不超过2000mg/d，不推荐用于10岁以下的儿童。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.儿童和青少年糖尿病及糖尿病前期患儿使用注意事项：无需以胰岛素作为起始治疗的10岁及以上T2DM患儿，应立即开始给予生活方式干预，不达标者以二甲双胍作为起始治疗药物。10岁及以上的糖尿病前期(IFG或lGT)患儿经3个月有效的生活方式干预(饮食控制、150min/周运动，减轻体重5%~10%)后，代谢异常指标仍无法逆转，建议使用二甲双胍治疗，起始剂量500mg，3次/d，最大剂量2000mg/d(V级)。二甲双胍可用于10岁及以上的T2DM的儿童或青少年，且最高剂量不超过2000mg/d，不推荐用于10岁以下的儿童。",
          "start_idx": 0,
          "end_idx": 262,
          "entities": [
            {
              "entity_id": "T482",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 11
            },
            {
              "entity_id": "T483",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 29,
              "end_idx": 32
            },
            {
              "entity_id": "T484",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 45,
              "end_idx": 47
            },
            {
              "entity_id": "T485",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 59,
              "end_idx": 65
            },
            {
              "entity_id": "T486",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 71,
              "end_idx": 75
            },
            {
              "entity_id": "T487",
              "entity": "糖尿病前期",
              "entity_type": "Disease",
              "start_idx": 12,
              "end_idx": 17
            },
            {
              "entity_id": "T488",
              "entity": "糖尿病前期",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 96
            },
            {
              "entity_id": "T489",
              "entity": "饮食控制",
              "entity_type": "Treatment",
              "start_idx": 121,
              "end_idx": 125
            },
            {
              "entity_id": "T490",
              "entity": "150min/周运动",
              "entity_type": "Treatment",
              "start_idx": 126,
              "end_idx": 136
            },
            {
              "entity_id": "T491",
              "entity": "减轻体重5%~10%",
              "entity_type": "Treatment",
              "start_idx": 137,
              "end_idx": 147
            },
            {
              "entity_id": "T492",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 166,
              "end_idx": 170
            },
            {
              "entity_id": "T493",
              "entity": "500mg",
              "entity_type": "Amount",
              "start_idx": 177,
              "end_idx": 182
            },
            {
              "entity_id": "T494",
              "entity": "3次/d",
              "entity_type": "Frequency",
              "start_idx": 183,
              "end_idx": 187
            },
            {
              "entity_id": "T495",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 192,
              "end_idx": 200
            },
            {
              "entity_id": "T496",
              "entity": "IFG",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 100
            },
            {
              "entity_id": "T497",
              "entity": "lGT",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 104
            },
            {
              "entity_id": "T498",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 49
            },
            {
              "entity_id": "T499",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 45,
              "end_idx": 47
            },
            {
              "entity_id": "T500",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 114,
              "end_idx": 120
            },
            {
              "entity_id": "T501",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 205,
              "end_idx": 209
            },
            {
              "entity_id": "T502",
              "entity": "2000mg/d",
              "entity_type": "Amount",
              "start_idx": 239,
              "end_idx": 247
            },
            {
              "entity_id": "T503",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 219,
              "end_idx": 223
            },
            {
              "entity_id": "T504",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 219,
              "end_idx": 221
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R236",
              "head_entity_id": "T485",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R237",
              "head_entity_id": "T486",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R238",
              "head_entity_id": "T489",
              "tail_entity_id": "T488"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R239",
              "head_entity_id": "T490",
              "tail_entity_id": "T488"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R240",
              "head_entity_id": "T491",
              "tail_entity_id": "T488"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R241",
              "head_entity_id": "T492",
              "tail_entity_id": "T488"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R242",
              "head_entity_id": "T500",
              "tail_entity_id": "T488"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R243",
              "head_entity_id": "T489",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R244",
              "head_entity_id": "T489",
              "tail_entity_id": "T497"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R245",
              "head_entity_id": "T490",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R246",
              "head_entity_id": "T490",
              "tail_entity_id": "T497"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R247",
              "head_entity_id": "T491",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R248",
              "head_entity_id": "T491",
              "tail_entity_id": "T497"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R249",
              "head_entity_id": "T495",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R250",
              "head_entity_id": "T494",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R251",
              "head_entity_id": "T492",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R252",
              "head_entity_id": "T492",
              "tail_entity_id": "T497"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R253",
              "head_entity_id": "T493",
              "tail_entity_id": "T492"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R254",
              "head_entity_id": "T500",
              "tail_entity_id": "T496"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R255",
              "head_entity_id": "T500",
              "tail_entity_id": "T497"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R256",
              "head_entity_id": "T499",
              "tail_entity_id": "T498"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R257",
              "head_entity_id": "T502",
              "tail_entity_id": "T501"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R258",
              "head_entity_id": "T501",
              "tail_entity_id": "T503"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R259",
              "head_entity_id": "T504",
              "tail_entity_id": "T503"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "32",
      "paragraph": "4.妊娠期糖尿病(GDM)患者使用注意事项：有GDM史的患者发现为糖尿病前期时，应接受生活方式干预或二甲双胍以预防糖尿病。患者一旦妊娠，建议改用胰岛素治疗(V级)。二甲双胍可降低PCOS患者妊娠早期的流产率和GDM的发生率。在控制孕妇体重和治疗IR方面有优势，孕早期口服二甲双胍没有增加胎儿重大畸形和新生儿并发症的风险，二甲双胍在FDA妊娠期用药分级中为B类药物。但我国药监部门尚未批准二甲双胍用于妊娠期妇女。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.妊娠期糖尿病(GDM)患者使用注意事项：有GDM史的患者发现为糖尿病前期时，应接受生活方式干预或二甲双胍以预防糖尿病。患者一旦妊娠，建议改用胰岛素治疗(V级)。二甲双胍可降低PCOS患者妊娠早期的流产率和GDM的发生率。在控制孕妇体重和治疗IR方面有优势，孕早期口服二甲双胍没有增加胎儿重大畸形和新生儿并发症的风险，二甲双胍在FDA妊娠期用药分级中为B类药物。",
          "start_idx": 0,
          "end_idx": 182,
          "entities": [
            {
              "entity_id": "T505",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 23,
              "end_idx": 26
            },
            {
              "entity_id": "T506",
              "entity": "糖尿病前期",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38
            },
            {
              "entity_id": "T507",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 57,
              "end_idx": 60
            },
            {
              "entity_id": "T508",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 43,
              "end_idx": 49
            },
            {
              "entity_id": "T509",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 50,
              "end_idx": 54
            },
            {
              "entity_id": "T510",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 72,
              "end_idx": 75
            },
            {
              "entity_id": "T511",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 82,
              "end_idx": 86
            },
            {
              "entity_id": "T512",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 89,
              "end_idx": 93
            },
            {
              "entity_id": "T513",
              "entity": "GDM",
              "entity_type": "Disease",
              "start_idx": 104,
              "end_idx": 107
            },
            {
              "entity_id": "T514",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 135,
              "end_idx": 139
            },
            {
              "entity_id": "T516",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 122,
              "end_idx": 124
            },
            {
              "entity_id": "T517",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 160,
              "end_idx": 164
            },
            {
              "entity_id": "T518",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 133,
              "end_idx": 135
            },
            {
              "entity_id": "T519",
              "entity": "妊娠期糖尿病(GDM)",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 13
            },
            {
              "entity_id": "T520",
              "entity": "妊娠期",
              "entity_type": "Class",
              "start_idx": 2,
              "end_idx": 5
            }
          ],
          "relations": [
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R260",
              "head_entity_id": "T508",
              "tail_entity_id": "T506"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R261",
              "head_entity_id": "T509",
              "tail_entity_id": "T506"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R262",
              "head_entity_id": "T511",
              "tail_entity_id": "T512"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R263",
              "head_entity_id": "T511",
              "tail_entity_id": "T513"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R264",
              "head_entity_id": "T518",
              "tail_entity_id": "T514"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R265",
              "head_entity_id": "T520",
              "tail_entity_id": "T519"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "但我国药监部门尚未批准二甲双胍用于妊娠期妇女。",
          "start_idx": 182,
          "end_idx": 205,
          "entities": [
            {
              "entity_id": "T515",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "33",
      "paragraph": "5.肝功能不全的T2DM患者使用注意事项：二甲双胍不经过肝脏代谢，无肝脏毒性。目前肝功能不全患者使用二甲双胍的临床资料较少。肝功能严重受损会明显限制乳酸的清除能力，建议血清转氨酶超过3倍正常上限时应避免使用，血清转氨酶轻度升高的患者使用时应密切监测肝功能。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.肝功能不全的T2DM患者使用注意事项：二甲双胍不经过肝脏代谢，无肝脏毒性。",
          "start_idx": 0,
          "end_idx": 39,
          "entities": [
            {
              "entity_id": "T521",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T522",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T523",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 8,
              "end_idx": 10
            },
            {
              "entity_id": "T524",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T529",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R266",
              "head_entity_id": "T529",
              "tail_entity_id": "T521"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R267",
              "head_entity_id": "T523",
              "tail_entity_id": "T522"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R268",
              "head_entity_id": "T524",
              "tail_entity_id": "T522"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "目前肝功能不全患者使用二甲双胍的临床资料较少。",
          "start_idx": 39,
          "end_idx": 62,
          "entities": [
            {
              "entity_id": "T525",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T526",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 11,
              "end_idx": 15
            },
            {
              "entity_id": "T530",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R269",
              "head_entity_id": "T530",
              "tail_entity_id": "T525"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R270",
              "head_entity_id": "T526",
              "tail_entity_id": "T525"
            }
          ]
        },
        {
          "sentence_id": "2",
          "sentence": "肝功能严重受损会明显限制乳酸的清除能力，建议血清转氨酶超过3倍正常上限时应避免使用，血清转氨酶轻度升高的患者使用时应密切监测肝功能。",
          "start_idx": 62,
          "end_idx": 128,
          "entities": [
            {
              "entity_id": "T527",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 22,
              "end_idx": 27
            },
            {
              "entity_id": "T528",
              "entity": "血清转氨酶",
              "entity_type": "Test_items",
              "start_idx": 42,
              "end_idx": 47
            },
            {
              "entity_id": "T531",
              "entity": "超过3倍正常上限",
              "entity_type": "Test_Value",
              "start_idx": 27,
              "end_idx": 35
            },
            {
              "entity_id": "T532",
              "entity": "轻度升高",
              "entity_type": "Test_Value",
              "start_idx": 47,
              "end_idx": 51
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "35",
      "paragraph": "7.造影或全麻术前患者使用注意事项：肾功能正常患者，造影前不必停用二甲双胍，但使用对比剂后应在医生的指导下停用48~72h，复查肾功能正常后可继续用药；而对于肾功能异常的患者，使用对比剂及全身麻醉术前48h应当暂时停用二甲双胍，之后还需停药48~72h，复查肾功能结果正常后可继续用药(V级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "7.造影或全麻术前患者使用注意事项：肾功能正常患者，造影前不必停用二甲双胍，但使用对比剂后应在医生的指导下停用48~72h，复查肾功能正常后可继续用药；而对于肾功能异常的患者，使用对比剂及全身麻醉术前48h应当暂时停用二甲双胍，之后还需停药48~72h，复查肾功能结果正常后可继续用药(V级)。",
          "start_idx": 0,
          "end_idx": 147,
          "entities": [
            {
              "entity_id": "T533",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 33,
              "end_idx": 37
            },
            {
              "entity_id": "T534",
              "entity": "肾功能异常",
              "entity_type": "Disease",
              "start_idx": 79,
              "end_idx": 84
            },
            {
              "entity_id": "T535",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 113
            },
            {
              "entity_id": "T536",
              "entity": "全麻术",
              "entity_type": "Operation",
              "start_idx": 5,
              "end_idx": 8
            },
            {
              "entity_id": "T537",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 79,
              "end_idx": 80
            },
            {
              "entity_id": "T538",
              "entity": "全身麻醉术",
              "entity_type": "Operation",
              "start_idx": 94,
              "end_idx": 99
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R271",
              "head_entity_id": "T537",
              "tail_entity_id": "T534"
            },
            {
              "relation_type": "Operation_Disease",
              "relation_id": "R272",
              "head_entity_id": "T538",
              "tail_entity_id": "T534"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R273",
              "head_entity_id": "T535",
              "tail_entity_id": "T534"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "36",
      "paragraph": "五、安全性",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "五、安全性",
          "start_idx": 0,
          "end_idx": 5,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "37",
      "paragraph": "1.禁忌证：(1)血清肌酐水平，男≥132μmol/L(1.5mg/dl)女≥124μmol/L(1.4mg/dl)，或eGFR<45ml/(min·1.73m2)禁用；(2)需要药物治疗的CHF和其他严重心、肺疾患；(3)严重感染和外伤、外科大手术、临床有低血压和缺氧等；(4)已知对盐酸二甲双胍过敏；(5)急、慢性代谢性酸中毒，包括有或无昏迷的糖尿病酮症酸中毒；(6)酗酒者；(7)接受血管内注射碘化对比剂者，应暂时停用；(8)维生素B12、叶酸缺乏未纠正者。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.禁忌证：(1)血清肌酐水平，男≥132μmol/L(1.5mg/dl)女≥124μmol/L(1.4mg/dl)，或eGFR<45ml/(min·1.73m2)禁用；(2)需要药物治疗的CHF和其他严重心、肺疾患；(3)严重感染和外伤、外科大手术、临床有低血压和缺氧等；(4)已知对盐酸二甲双胍过敏；(5)急、慢性代谢性酸中毒，包括有或无昏迷的糖尿病酮症酸中毒；(6)酗酒者；(7)接受血管内注射碘化对比剂者，应暂时停用；(8)维生素B12、叶酸缺乏未纠正者。",
          "start_idx": 0,
          "end_idx": 232,
          "entities": [
            {
              "entity_id": "T539",
              "entity": "血清肌酐水平",
              "entity_type": "Test_items",
              "start_idx": 9,
              "end_idx": 15
            },
            {
              "entity_id": "T540",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 64
            },
            {
              "entity_id": "T541",
              "entity": "<45ml/(min·1.73m2)",
              "entity_type": "Test_Value",
              "start_idx": 64,
              "end_idx": 82
            },
            {
              "entity_id": "T542",
              "entity": "CHF",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 98
            },
            {
              "entity_id": "T543",
              "entity": "低血压",
              "entity_type": "ADE",
              "start_idx": 129,
              "end_idx": 132
            },
            {
              "entity_id": "T544",
              "entity": "急、慢性代谢性酸中毒",
              "entity_type": "Disease",
              "start_idx": 155,
              "end_idx": 165
            },
            {
              "entity_id": "T545",
              "entity": "盐酸二甲双胍",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 149
            },
            {
              "entity_id": "T546",
              "entity": "糖尿病酮症酸中毒",
              "entity_type": "Disease",
              "start_idx": 174,
              "end_idx": 182
            },
            {
              "entity_id": "T547",
              "entity": "心",
              "entity_type": "Anatomy",
              "start_idx": 103,
              "end_idx": 104
            },
            {
              "entity_id": "T548",
              "entity": "肺",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 106
            },
            {
              "entity_id": "T549",
              "entity": "≥132μmol/L(1.5mg/dl)",
              "entity_type": "Test_Value",
              "start_idx": 17,
              "end_idx": 37
            },
            {
              "entity_id": "T550",
              "entity": "≥124μmol/L(1.4mg/dl)",
              "entity_type": "Test_Value",
              "start_idx": 38,
              "end_idx": 58
            },
            {
              "entity_id": "T551",
              "entity": "缺氧",
              "entity_type": "ADE",
              "start_idx": 133,
              "end_idx": 135
            },
            {
              "entity_id": "T552",
              "entity": "感染",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 116
            },
            {
              "entity_id": "T553",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 112,
              "end_idx": 114
            },
            {
              "entity_id": "T554",
              "entity": "外伤",
              "entity_type": "Disease",
              "start_idx": 117,
              "end_idx": 119
            },
            {
              "entity_id": "T555",
              "entity": "心、肺疾患",
              "entity_type": "Disease",
              "start_idx": 103,
              "end_idx": 108
            },
            {
              "entity_id": "T556",
              "entity": "严重",
              "entity_type": "Level",
              "start_idx": 101,
              "end_idx": 103
            },
            {
              "entity_id": "T557",
              "entity": "过敏",
              "entity_type": "ADE",
              "start_idx": 149,
              "end_idx": 151
            },
            {
              "entity_id": "T558",
              "entity": "急、慢性",
              "entity_type": "Class",
              "start_idx": 155,
              "end_idx": 159
            },
            {
              "entity_id": "T559",
              "entity": "代谢性",
              "entity_type": "Class",
              "start_idx": 159,
              "end_idx": 162
            },
            {
              "entity_id": "T560",
              "entity": "碘化对比剂",
              "entity_type": "Drug",
              "start_idx": 200,
              "end_idx": 205
            },
            {
              "entity_id": "T561",
              "entity": "血管内注射",
              "entity_type": "Method",
              "start_idx": 195,
              "end_idx": 200
            },
            {
              "entity_id": "T562",
              "entity": "维生素B12、叶酸缺乏",
              "entity_type": "Disease",
              "start_idx": 216,
              "end_idx": 227
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R274",
              "head_entity_id": "T558",
              "tail_entity_id": "T544"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R275",
              "head_entity_id": "T559",
              "tail_entity_id": "T544"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R276",
              "head_entity_id": "T557",
              "tail_entity_id": "T545"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R277",
              "head_entity_id": "T547",
              "tail_entity_id": "T555"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R278",
              "head_entity_id": "T548",
              "tail_entity_id": "T555"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R279",
              "head_entity_id": "T561",
              "tail_entity_id": "T560"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "38",
      "paragraph": "2.常见不良反应：常见不良反应包括腹泻、恶心、呕吐、胃胀、乏力、消化不良、腹部不适及头痛。这些不良反应的发生常见于药物治疗的早期，",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.常见不良反应：常见不良反应包括腹泻、恶心、呕吐、胃胀、乏力、消化不良、腹部不适及头痛。",
          "start_idx": 0,
          "end_idx": 45,
          "entities": [
            {
              "entity_id": "T563",
              "entity": "腹泻",
              "entity_type": "ADE",
              "start_idx": 17,
              "end_idx": 19
            },
            {
              "entity_id": "T564",
              "entity": "恶心",
              "entity_type": "ADE",
              "start_idx": 20,
              "end_idx": 22
            },
            {
              "entity_id": "T565",
              "entity": "呕吐",
              "entity_type": "ADE",
              "start_idx": 23,
              "end_idx": 25
            },
            {
              "entity_id": "T566",
              "entity": "胃胀",
              "entity_type": "ADE",
              "start_idx": 26,
              "end_idx": 28
            },
            {
              "entity_id": "T567",
              "entity": "乏力",
              "entity_type": "ADE",
              "start_idx": 29,
              "end_idx": 31
            },
            {
              "entity_id": "T568",
              "entity": "消化不良",
              "entity_type": "ADE",
              "start_idx": 32,
              "end_idx": 36
            },
            {
              "entity_id": "T569",
              "entity": "腹部不适",
              "entity_type": "ADE",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T570",
              "entity": "头痛",
              "entity_type": "ADE",
              "start_idx": 42,
              "end_idx": 44
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "这些不良反应的发生常见于药物治疗的早期，",
          "start_idx": 45,
          "end_idx": 65,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "39",
      "paragraph": "绝大多数患者可耐受。随着治疗时间的延长，上述不良反应可基本消失。小剂量开始，逐渐增加剂量是减少治疗初期不良反应发生的有效方法。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "绝大多数患者可耐受。",
          "start_idx": 0,
          "end_idx": 10,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "1",
          "sentence": "随着治疗时间的延长，上述不良反应可基本消失。",
          "start_idx": 10,
          "end_idx": 32,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "小剂量开始，逐渐增加剂量是减少治疗初期不良反应发生的有效方法。",
          "start_idx": 32,
          "end_idx": 63,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "40",
      "paragraph": "3.胃肠道反应与剂量的关系及处理原则：二甲双胍引起的胃肠道反应发生多出现在治疗的早期(绝大多数发生于前10周)，多数患者随着治疗时间的延长，可逐渐耐受或症状消失。国外报道，即使二甲双胍较大剂量(1000mg/d)起始治疗，其胃肠道反应发生率为28%，在1000mg增至2000mg/d时胃肠道反应差异无统计学意义。国内报道，二甲双胍的胃肠道反应发生率为15%(Ⅰ级)，如果增加剂量后发生严重胃肠道反应，可以降至之前较低的剂量，耐受后可再尝试增大剂量，缓释制剂也可减少患者的胃肠道症状。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.胃肠道反应与剂量的关系及处理原则：二甲双胍引起的胃肠道反应发生多出现在治疗的早期(绝大多数发生于前10周)，多数患者随着治疗时间的延长，可逐渐耐受或症状消失。国外报道，即使二甲双胍较大剂量(1000mg/d)起始治疗，其胃肠道反应发生率为28%，在1000mg增至2000mg/d时胃肠道反应差异无统计学意义。",
          "start_idx": 0,
          "end_idx": 157,
          "entities": [
            {
              "entity_id": "T571",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T572",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23
            },
            {
              "entity_id": "T573",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 26,
              "end_idx": 31
            },
            {
              "entity_id": "T574",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 88,
              "end_idx": 92
            },
            {
              "entity_id": "T575",
              "entity": "1000mg/d",
              "entity_type": "Amount",
              "start_idx": 97,
              "end_idx": 105
            },
            {
              "entity_id": "T576",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 112,
              "end_idx": 117
            },
            {
              "entity_id": "T577",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 143,
              "end_idx": 148
            },
            {
              "entity_id": "T578",
              "entity": "1000mg增至2000mg/d",
              "entity_type": "Amount",
              "start_idx": 126,
              "end_idx": 142
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R280",
              "head_entity_id": "T573",
              "tail_entity_id": "T572"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R281",
              "head_entity_id": "T575",
              "tail_entity_id": "T574"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R282",
              "head_entity_id": "T576",
              "tail_entity_id": "T574"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R283",
              "head_entity_id": "T577",
              "tail_entity_id": "T574"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R284",
              "head_entity_id": "T578",
              "tail_entity_id": "T574"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "国内报道，二甲双胍的胃肠道反应发生率为15%(Ⅰ级)，如果增加剂量后发生严重胃肠道反应，可以降至之前较低的剂量，耐受后可再尝试增大剂量，缓释制剂也可减少患者的胃肠道症状。",
          "start_idx": 157,
          "end_idx": 242,
          "entities": [
            {
              "entity_id": "T579",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 5,
              "end_idx": 9
            },
            {
              "entity_id": "T580",
              "entity": "胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 10,
              "end_idx": 15
            },
            {
              "entity_id": "T581",
              "entity": "严重胃肠道反应",
              "entity_type": "ADE",
              "start_idx": 36,
              "end_idx": 43
            },
            {
              "entity_id": "T582",
              "entity": "胃肠道症状",
              "entity_type": "ADE",
              "start_idx": 79,
              "end_idx": 84
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R285",
              "head_entity_id": "T580",
              "tail_entity_id": "T579"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "41",
      "paragraph": "4.对维生素B12的吸收的影响：已有多项交叉横断面试验及随机对照研究显示，长期服用二甲双胍可引起维生素B12水平的下降。其机制可能与以下因素有关(1)小肠蠕动的改变刺激肠道细菌过度生长，竞争性抑制维生素B12的吸收；(2)维生素B12内因子水平的变化及钴胺素内吞受体的相互作用；(3)二甲双胍可抑制回肠末端维生素B12内因子复合物钙依赖性吸收(这种抑制作用可以通过补充钙剂逆转)。二甲双胍治疗引起巨幼红细胞性贫血罕见，如发生应排除维生素B12缺乏。建议在长期使用二甲双胍治疗患者中适当补充维生素B12。不建议在服用二甲双胍的患者中常规监测维生素B12的水平。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.对维生素B12的吸收的影响：已有多项交叉横断面试验及随机对照研究显示，长期服用二甲双胍可引起维生素B12水平的下降。其机制可能与以下因素有关(1)小肠蠕动的改变刺激肠道细菌过度生长，竞争性抑制维生素B12的吸收；(2)维生素B12内因子水平的变化及钴胺素内吞受体的相互作用；(3)二甲双胍可抑制回肠末端维生素B12内因子复合物钙依赖性吸收(这种抑制作用可以通过补充钙剂逆转)。二甲双胍治疗引起巨幼红细胞性贫血罕见，如发生应排除维生素B12缺乏。",
          "start_idx": 0,
          "end_idx": 224,
          "entities": [
            {
              "entity_id": "T583",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 45
            },
            {
              "entity_id": "T584",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 142,
              "end_idx": 146
            },
            {
              "entity_id": "T585",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 190,
              "end_idx": 194
            },
            {
              "entity_id": "T586",
              "entity": "巨幼红细胞性贫血",
              "entity_type": "ADE",
              "start_idx": 198,
              "end_idx": 206
            },
            {
              "entity_id": "T587",
              "entity": "维生素B12缺乏",
              "entity_type": "Disease",
              "start_idx": 215,
              "end_idx": 223
            },
            {
              "entity_id": "T591",
              "entity": "维生素B12水平的下降",
              "entity_type": "ADE",
              "start_idx": 48,
              "end_idx": 59
            },
            {
              "entity_id": "T592",
              "entity": "钙剂",
              "entity_type": "Drug",
              "start_idx": 184,
              "end_idx": 186
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R286",
              "head_entity_id": "T591",
              "tail_entity_id": "T583"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R287",
              "head_entity_id": "T586",
              "tail_entity_id": "T585"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "建议在长期使用二甲双胍治疗患者中适当补充维生素B12。",
          "start_idx": 224,
          "end_idx": 251,
          "entities": [
            {
              "entity_id": "T588",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 7,
              "end_idx": 11
            },
            {
              "entity_id": "T589",
              "entity": "维生素B12",
              "entity_type": "Drug",
              "start_idx": 20,
              "end_idx": 26
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "不建议在服用二甲双胍的患者中常规监测维生素B12的水平。",
          "start_idx": 251,
          "end_idx": 279,
          "entities": [
            {
              "entity_id": "T590",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 6,
              "end_idx": 10
            },
            {
              "entity_id": "T593",
              "entity": "监测维生素B12的水平",
              "entity_type": "Test_items",
              "start_idx": 16,
              "end_idx": 27
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "42",
      "paragraph": "5.是否损伤肝肾：二甲双胍主要以原形由肾脏从尿中排出，清除迅速，12~24h大约可清除90%。二甲双胍肾清除率约为肌酐清除率的3.5倍，且经肾小管排泄是二甲双胍清除的主要途径。因此，二甲双胍对肾脏没有损害。有研究提示，二甲双胍可能具有肾脏保护作用。二甲双胍通过胃肠道吸收进行血液循环，几乎不与血浆白蛋白结合，不经过肝脏代谢，不竞争P450酶，在体内也不降解，面是直接作用于肝脏和肌肉，减少肝糖异生，增加肌肉葡萄糖酵解。因此二甲双胍无肝毒性，推荐剂量范围内用药的肝功能正常者，不会造成肝损害。但肝功能受损者使用二甲双胍时应谨慎，因为肝功能受损会明显限制其对乳酸盐的清除能力。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "5.是否损伤肝肾：二甲双胍主要以原形由肾脏从尿中排出，清除迅速，12~24h大约可清除90%。二甲双胍肾清除率约为肌酐清除率的3.5倍，且经肾小管排泄是二甲双胍清除的主要途径。因此，二甲双胍对肾脏没有损害。有研究提示，二甲双胍可能具有肾脏保护作用。二甲双胍通过胃肠道吸收进行血液循环，几乎不与血浆白蛋白结合，不经过肝脏代谢，不竞争P450酶，在体内也不降解，面是直接作用于肝脏和肌肉，减少肝糖异生，增加肌肉葡萄糖酵解。因此二甲双胍无肝毒性，推荐剂量范围内用药的肝功能正常者，不会造成肝损害。但肝功能受损者使用二甲双胍时应谨慎，因为肝功能受损会明显限制其对乳酸盐的清除能力。",
          "start_idx": 0,
          "end_idx": 286,
          "entities": [
            {
              "entity_id": "T594",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 9,
              "end_idx": 13
            },
            {
              "entity_id": "T595",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 47,
              "end_idx": 51
            },
            {
              "entity_id": "T596",
              "entity": "肌酐清除率",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 62
            },
            {
              "entity_id": "T597",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 76,
              "end_idx": 80
            },
            {
              "entity_id": "T598",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 91,
              "end_idx": 95
            },
            {
              "entity_id": "T599",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 109,
              "end_idx": 113
            },
            {
              "entity_id": "T600",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 124,
              "end_idx": 128
            },
            {
              "entity_id": "T601",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 211,
              "end_idx": 215
            },
            {
              "entity_id": "T602",
              "entity": "肝损害",
              "entity_type": "Disease",
              "start_idx": 241,
              "end_idx": 244
            },
            {
              "entity_id": "T603",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 254,
              "end_idx": 258
            },
            {
              "entity_id": "T604",
              "entity": "肝功能受损",
              "entity_type": "Disease",
              "start_idx": 246,
              "end_idx": 251
            },
            {
              "entity_id": "T605",
              "entity": "肝功能受损",
              "entity_type": "Disease",
              "start_idx": 265,
              "end_idx": 270
            },
            {
              "entity_id": "T606",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 241,
              "end_idx": 242
            },
            {
              "entity_id": "T607",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 246,
              "end_idx": 247
            },
            {
              "entity_id": "T608",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 265,
              "end_idx": 266
            },
            {
              "entity_id": "T609",
              "entity": "3.5倍",
              "entity_type": "Test_Value",
              "start_idx": 63,
              "end_idx": 67
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R288",
              "head_entity_id": "T606",
              "tail_entity_id": "T602"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R289",
              "head_entity_id": "T603",
              "tail_entity_id": "T604"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R290",
              "head_entity_id": "T607",
              "tail_entity_id": "T604"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R291",
              "head_entity_id": "T608",
              "tail_entity_id": "T605"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "43",
      "paragraph": "6.二甲双胍与乳酸酸中毒：目前尚无确切的证据支持二甲双胍的使用与乳酸酸中毒有关，肝肾功能正常患者长期应用不增加乳酸酸中毒风险。COSMIC研究显示，使用二甲双胍的乳酸酸中毒发生率与其他降糖治疗差异无统计学意义(Ⅰ级)。荟萃分析显示，在肾功能正常的患者中使用二甲双胍不增加乳酸酸中毒风险，且二甲双胍发生乳酸酸中毒的概率并不比其他口服降糖药物高。因二甲双胍直接以原形经肾脏排泄，因此有肾功能损害时易发生二甲双胍与乳酸在体内蓄积，有可能会增加乳酸酸中毒风险。建议肾功能受损[eGFR<45ml/(min·1.73m2)]和低氧血症患者应避免使用。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.二甲双胍与乳酸酸中毒：目前尚无确切的证据支持二甲双胍的使用与乳酸酸中毒有关，肝肾功能正常患者长期应用不增加乳酸酸中毒风险。COSMIC研究显示，使用二甲双胍的乳酸酸中毒发生率与其他降糖治疗差异无统计学意义(Ⅰ级)。荟萃分析显示，在肾功能正常的患者中使用二甲双胍不增加乳酸酸中毒风险，且二甲双胍发生乳酸酸中毒的概率并不比其他口服降糖药物高。因二甲双胍直接以原形经肾脏排泄，因此有肾功能损害时易发生二甲双胍与乳酸在体内蓄积，有可能会增加乳酸酸中毒风险。建议肾功能受损[eGFR<45ml/(min·1.73m2)]和低氧血症患者应避免使用。",
          "start_idx": 0,
          "end_idx": 270,
          "entities": [
            {
              "entity_id": "T610",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T611",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 7,
              "end_idx": 12
            },
            {
              "entity_id": "T612",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 28
            },
            {
              "entity_id": "T613",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 32,
              "end_idx": 37
            },
            {
              "entity_id": "T614",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 55,
              "end_idx": 60
            },
            {
              "entity_id": "T615",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 76,
              "end_idx": 80
            },
            {
              "entity_id": "T616",
              "entity": "乳酸酸中毒",
              "entity_type": "ADE",
              "start_idx": 81,
              "end_idx": 86
            },
            {
              "entity_id": "T617",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 128,
              "end_idx": 132
            },
            {
              "entity_id": "T618",
              "entity": "乳酸酸中毒",
              "entity_type": "Disease",
              "start_idx": 135,
              "end_idx": 140
            },
            {
              "entity_id": "T619",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 144,
              "end_idx": 148
            },
            {
              "entity_id": "T620",
              "entity": "乳酸酸中毒",
              "entity_type": "ADE",
              "start_idx": 150,
              "end_idx": 155
            },
            {
              "entity_id": "T621",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 172,
              "end_idx": 176
            },
            {
              "entity_id": "T622",
              "entity": "肾功能损害",
              "entity_type": "Disease",
              "start_idx": 190,
              "end_idx": 195
            },
            {
              "entity_id": "T623",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 199,
              "end_idx": 203
            },
            {
              "entity_id": "T624",
              "entity": "乳酸酸中毒",
              "entity_type": "ADE",
              "start_idx": 218,
              "end_idx": 223
            },
            {
              "entity_id": "T625",
              "entity": "肾功能受损",
              "entity_type": "Disease",
              "start_idx": 228,
              "end_idx": 233
            },
            {
              "entity_id": "T626",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 234,
              "end_idx": 238
            },
            {
              "entity_id": "T627",
              "entity": "<45ml/(min·1.73m2)",
              "entity_type": "Test_Value",
              "start_idx": 238,
              "end_idx": 256
            },
            {
              "entity_id": "T628",
              "entity": "低氧血症",
              "entity_type": "Disease",
              "start_idx": 258,
              "end_idx": 262
            },
            {
              "entity_id": "T629",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 190,
              "end_idx": 191
            },
            {
              "entity_id": "T630",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 228,
              "end_idx": 229
            },
            {
              "entity_id": "T631",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 163,
              "end_idx": 165
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R292",
              "head_entity_id": "T616",
              "tail_entity_id": "T615"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R293",
              "head_entity_id": "T620",
              "tail_entity_id": "T619"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R294",
              "head_entity_id": "T629",
              "tail_entity_id": "T622"
            },
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R295",
              "head_entity_id": "T624",
              "tail_entity_id": "T623"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R296",
              "head_entity_id": "T626",
              "tail_entity_id": "T625"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R297",
              "head_entity_id": "T630",
              "tail_entity_id": "T625"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "44",
      "paragraph": "7.与非降糖药物的相互作用：(1)使用氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等经肾小管排泌的阳离子药物，其影响肾功能或二甲双胍分布，应密切监测血糖并调整二甲双胍和/或相互作用的剂量；(2)同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物需密切监测血糖。而在这些药物停用后，要密切注意低血糖的发生：合并服用氯磺丙脲的患者在换用二甲双胍的最初2周要密切监测血糖，氯磺丙脲在体内有较长潜留，易发生低血糖；(3)二甲双胍有增加华法林的抗凝血倾向；(4)树脂类药物，如苏合香、血竭、乳香等与二甲双胍合用会减少其吸收。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "7.与非降糖药物的相互作用：(1)使用氨氯吡咪、地高辛、吗啡、普鲁卡因胺、奎尼丁、奎宁、雷尼替丁、氨苯蝶啶、甲氧苄氨嘧啶和万古霉素等经肾小管排泌的阳离子药物，其影响肾功能或二甲双胍分布，应密切监测血糖并调整二甲双胍和/或相互作用的剂量；(2)同时服用噻嗪类药物或其他利尿剂、糖皮质激素、吩噻嗪、甲状腺制剂、雌激素、口服避孕药、苯妥英、烟碱酸、拟交感神经药、钙离子通道阻滞剂和异烟肼等可引起血糖升高的药物需密切监测血糖。而在这些药物停用后，要密切注意低血糖的发生：合并服用氯磺丙脲的患者在换用二甲双胍的最初2周要密切监测血糖，氯磺丙脲在体内有较长潜留，易发生低血糖；(3)二甲双胍有增加华法林的抗凝血倾向；(4)树脂类药物，如苏合香、血竭、乳香等与二甲双胍合用会减少其吸收。",
          "start_idx": 0,
          "end_idx": 336,
          "entities": [
            {
              "entity_id": "T632",
              "entity": "氨氯吡咪",
              "entity_type": "Drug",
              "start_idx": 19,
              "end_idx": 23
            },
            {
              "entity_id": "T633",
              "entity": "地高辛",
              "entity_type": "Drug",
              "start_idx": 24,
              "end_idx": 27
            },
            {
              "entity_id": "T634",
              "entity": "吗啡",
              "entity_type": "Drug",
              "start_idx": 28,
              "end_idx": 30
            },
            {
              "entity_id": "T635",
              "entity": "普鲁卡因胺",
              "entity_type": "Drug",
              "start_idx": 31,
              "end_idx": 36
            },
            {
              "entity_id": "T636",
              "entity": "奎尼丁",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 40
            },
            {
              "entity_id": "T637",
              "entity": "奎宁",
              "entity_type": "Drug",
              "start_idx": 41,
              "end_idx": 43
            },
            {
              "entity_id": "T638",
              "entity": "雷尼替丁",
              "entity_type": "Drug",
              "start_idx": 44,
              "end_idx": 48
            },
            {
              "entity_id": "T639",
              "entity": "氨苯蝶啶",
              "entity_type": "Drug",
              "start_idx": 49,
              "end_idx": 53
            },
            {
              "entity_id": "T640",
              "entity": "甲氧苄氨嘧啶",
              "entity_type": "Drug",
              "start_idx": 54,
              "end_idx": 60
            },
            {
              "entity_id": "T641",
              "entity": "万古霉素",
              "entity_type": "Drug",
              "start_idx": 61,
              "end_idx": 65
            },
            {
              "entity_id": "T642",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 86,
              "end_idx": 90
            },
            {
              "entity_id": "T643",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 98,
              "end_idx": 100
            },
            {
              "entity_id": "T644",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 103,
              "end_idx": 107
            },
            {
              "entity_id": "T645",
              "entity": "噻嗪类药物",
              "entity_type": "Drug",
              "start_idx": 125,
              "end_idx": 130
            },
            {
              "entity_id": "T646",
              "entity": "糖皮质激素",
              "entity_type": "Drug",
              "start_idx": 137,
              "end_idx": 142
            },
            {
              "entity_id": "T647",
              "entity": "吩噻嗪",
              "entity_type": "Drug",
              "start_idx": 143,
              "end_idx": 146
            },
            {
              "entity_id": "T648",
              "entity": "甲状腺制剂",
              "entity_type": "Drug",
              "start_idx": 147,
              "end_idx": 152
            },
            {
              "entity_id": "T649",
              "entity": "雌激素",
              "entity_type": "Drug",
              "start_idx": 153,
              "end_idx": 156
            },
            {
              "entity_id": "T650",
              "entity": "苯妥英",
              "entity_type": "Drug",
              "start_idx": 163,
              "end_idx": 166
            },
            {
              "entity_id": "T651",
              "entity": "烟碱酸",
              "entity_type": "Drug",
              "start_idx": 167,
              "end_idx": 170
            },
            {
              "entity_id": "T652",
              "entity": "拟交感神经药",
              "entity_type": "Drug",
              "start_idx": 171,
              "end_idx": 177
            },
            {
              "entity_id": "T653",
              "entity": "钙离子通道阻滞剂",
              "entity_type": "Drug",
              "start_idx": 178,
              "end_idx": 186
            },
            {
              "entity_id": "T654",
              "entity": "异烟肼",
              "entity_type": "Drug",
              "start_idx": 187,
              "end_idx": 190
            },
            {
              "entity_id": "T655",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 194,
              "end_idx": 196
            },
            {
              "entity_id": "T656",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 206,
              "end_idx": 208
            },
            {
              "entity_id": "T657",
              "entity": "低血糖",
              "entity_type": "Disease",
              "start_idx": 224,
              "end_idx": 227
            },
            {
              "entity_id": "T658",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 235,
              "end_idx": 239
            },
            {
              "entity_id": "T659",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 245,
              "end_idx": 249
            },
            {
              "entity_id": "T660",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 259,
              "end_idx": 261
            },
            {
              "entity_id": "T661",
              "entity": "氯磺丙脲",
              "entity_type": "Drug",
              "start_idx": 262,
              "end_idx": 266
            },
            {
              "entity_id": "T662",
              "entity": "低血糖",
              "entity_type": "ADE",
              "start_idx": 278,
              "end_idx": 281
            },
            {
              "entity_id": "T663",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 285,
              "end_idx": 289
            },
            {
              "entity_id": "T664",
              "entity": "苏合香",
              "entity_type": "Drug",
              "start_idx": 312,
              "end_idx": 315
            },
            {
              "entity_id": "T665",
              "entity": "血竭",
              "entity_type": "Drug",
              "start_idx": 316,
              "end_idx": 318
            },
            {
              "entity_id": "T666",
              "entity": "乳香",
              "entity_type": "Drug",
              "start_idx": 319,
              "end_idx": 321
            },
            {
              "entity_id": "T667",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 323,
              "end_idx": 327
            },
            {
              "entity_id": "T668",
              "entity": "华法林",
              "entity_type": "Drug",
              "start_idx": 292,
              "end_idx": 295
            },
            {
              "entity_id": "T669",
              "entity": "口服避孕药",
              "entity_type": "Drug",
              "start_idx": 157,
              "end_idx": 162
            },
            {
              "entity_id": "T670",
              "entity": "口服",
              "entity_type": "Method",
              "start_idx": 157,
              "end_idx": 159
            },
            {
              "entity_id": "T671",
              "entity": "升高",
              "entity_type": "Test_Value",
              "start_idx": 196,
              "end_idx": 198
            },
            {
              "entity_id": "T672",
              "entity": "利尿剂",
              "entity_type": "Drug",
              "start_idx": 133,
              "end_idx": 136
            }
          ],
          "relations": [
            {
              "relation_type": "ADE_Drug",
              "relation_id": "R298",
              "head_entity_id": "T662",
              "tail_entity_id": "T661"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R299",
              "head_entity_id": "T670",
              "tail_entity_id": "T669"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "45",
      "paragraph": "六、心血管益处",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "六、心血管益处",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "46",
      "paragraph": "1.心血管保护作用：二甲双胍通过有效改善糖尿病和非糖尿病患者的IR，降低基础和负荷后胰岛素水平，起到直接或间接的心血管保护作用(Ⅰ级)。UKPDS显示，使用二甲双胍的肥胖T2DM患者的全因死亡风险相对下降35%，心肌梗死风险下降39%；UKPDS10年随访显示，二甲双胍治疗组大血管并发症及死亡风险的获益具有延续效应，且降低死亡和心肌梗死的作用优于磺脲类和胰岛素。REACH研究结果提示，二甲双胍治疗2年，全因死亡相对风险下降24%，HOME研究结果提示，二甲双胍联合胰岛素比单用胰岛素可以减少大血管事件风险，中国SPREAD研究结果显示，对于有冠心病病史的T2DM患者，与格列吡嗪组相比，二甲双胍组的主要终点事件发生风险降低46%(Ⅰ级)。二甲双胍是目前唯一被2013AACE指南推荐有心血管获益证据的降糖药物。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.心血管保护作用：二甲双胍通过有效改善糖尿病和非糖尿病患者的IR，降低基础和负荷后胰岛素水平，起到直接或间接的心血管保护作用(Ⅰ级)。UKPDS显示，使用二甲双胍的肥胖T2DM患者的全因死亡风险相对下降35%，心肌梗死风险下降39%；UKPDS10年随访显示，二甲双胍治疗组大血管并发症及死亡风险的获益具有延续效应，且降低死亡和心肌梗死的作用优于磺脲类和胰岛素。",
          "start_idx": 0,
          "end_idx": 182,
          "entities": [
            {
              "entity_id": "T673",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23
            },
            {
              "entity_id": "T674",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 10,
              "end_idx": 14
            },
            {
              "entity_id": "T675",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 25,
              "end_idx": 28
            },
            {
              "entity_id": "T676",
              "entity": "IR",
              "entity_type": "Pathogenesis",
              "start_idx": 31,
              "end_idx": 33
            },
            {
              "entity_id": "T677",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 85,
              "end_idx": 89
            },
            {
              "entity_id": "T678",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 85,
              "end_idx": 87
            },
            {
              "entity_id": "T679",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 78,
              "end_idx": 82
            },
            {
              "entity_id": "T680",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 83,
              "end_idx": 85
            },
            {
              "entity_id": "T681",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 106,
              "end_idx": 110
            },
            {
              "entity_id": "T682",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 131,
              "end_idx": 135
            },
            {
              "entity_id": "T683",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 138,
              "end_idx": 141
            },
            {
              "entity_id": "T684",
              "entity": "心肌梗死",
              "entity_type": "Disease",
              "start_idx": 165,
              "end_idx": 169
            },
            {
              "entity_id": "T685",
              "entity": "磺脲类",
              "entity_type": "Drug",
              "start_idx": 174,
              "end_idx": 177
            },
            {
              "entity_id": "T686",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 178,
              "end_idx": 181
            },
            {
              "entity_id": "T698",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 106,
              "end_idx": 108
            },
            {
              "entity_id": "T699",
              "entity": "心肌",
              "entity_type": "Anatomy",
              "start_idx": 165,
              "end_idx": 167
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R300",
              "head_entity_id": "T674",
              "tail_entity_id": "T673"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R301",
              "head_entity_id": "T676",
              "tail_entity_id": "T673"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R302",
              "head_entity_id": "T674",
              "tail_entity_id": "T675"
            },
            {
              "relation_type": "Pathogenesis_Disease",
              "relation_id": "R303",
              "head_entity_id": "T676",
              "tail_entity_id": "T675"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R304",
              "head_entity_id": "T679",
              "tail_entity_id": "T677"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R305",
              "head_entity_id": "T678",
              "tail_entity_id": "T677"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R306",
              "head_entity_id": "T683",
              "tail_entity_id": "T677"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R307",
              "head_entity_id": "T679",
              "tail_entity_id": "T680"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R308",
              "head_entity_id": "T683",
              "tail_entity_id": "T680"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R309",
              "head_entity_id": "T698",
              "tail_entity_id": "T681"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R310",
              "head_entity_id": "T699",
              "tail_entity_id": "T684"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "REACH研究结果提示，二甲双胍治疗2年，全因死亡相对风险下降24%，HOME研究结果提示，二甲双胍联合胰岛素比单用胰岛素可以减少大血管事件风险，中国SPREAD研究结果显示，对于有冠心病病史的T2DM患者，与格列吡嗪组相比，二甲双胍组的主要终点事件发生风险降低46%(Ⅰ级)。",
          "start_idx": 182,
          "end_idx": 321,
          "entities": [
            {
              "entity_id": "T687",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16
            },
            {
              "entity_id": "T688",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 46,
              "end_idx": 50
            },
            {
              "entity_id": "T689",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 55
            },
            {
              "entity_id": "T690",
              "entity": "胰岛素",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 61
            },
            {
              "entity_id": "T691",
              "entity": "大血管事件",
              "entity_type": "Disease",
              "start_idx": 65,
              "end_idx": 70
            },
            {
              "entity_id": "T692",
              "entity": "冠心病",
              "entity_type": "Disease",
              "start_idx": 91,
              "end_idx": 94
            },
            {
              "entity_id": "T693",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 97,
              "end_idx": 101
            },
            {
              "entity_id": "T694",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 97,
              "end_idx": 99
            },
            {
              "entity_id": "T695",
              "entity": "格列吡嗪",
              "entity_type": "Drug",
              "start_idx": 105,
              "end_idx": 109
            },
            {
              "entity_id": "T696",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 117
            },
            {
              "entity_id": "T700",
              "entity": "大血管",
              "entity_type": "Anatomy",
              "start_idx": 65,
              "end_idx": 68
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R311",
              "head_entity_id": "T700",
              "tail_entity_id": "T691"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R312",
              "head_entity_id": "T694",
              "tail_entity_id": "T693"
            }
          ]
        },
        {
          "sentence_id": "2",
          "sentence": "二甲双胍是目前唯一被2013AACE指南推荐有心血管获益证据的降糖药物。",
          "start_idx": 321,
          "end_idx": 357,
          "entities": [
            {
              "entity_id": "T697",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 0,
              "end_idx": 4
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "47",
      "paragraph": "2.心血管保护作用机制：二甲双胍可能通过减少心血管疾病的危险因素而达到心血管保护。心血管疾病的危险因素包括血脂异常、IR、肥胖、高血压、NAFLD等。控制危险因素是心血管保护的重要方式之一。二甲双胍目前已经被证实可以降低血糖、改善NAFLD和IR(尤其是肝脏和肌肉)、减轻体重、改善血脂(主要是改善TG、LDL-C及TC水平，对HDL-C改变不明显)和抗凝等此外，二甲双胍可以直接改善血管内皮细胞功能，增加血流量。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.心血管保护作用机制：二甲双胍可能通过减少心血管疾病的危险因素而达到心血管保护。心血管疾病的危险因素包括血脂异常、IR、肥胖、高血压、NAFLD等。控制危险因素是心血管保护的重要方式之一。二甲双胍目前已经被证实可以降低血糖、改善NAFLD和IR(尤其是肝脏和肌肉)、减轻体重、改善血脂(主要是改善TG、LDL-C及TC水平，对HDL-C改变不明显)和抗凝等此外，二甲双胍可以直接改善血管内皮细胞功能，增加血流量。",
          "start_idx": 0,
          "end_idx": 207,
          "entities": [
            {
              "entity_id": "T701",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 12,
              "end_idx": 16
            },
            {
              "entity_id": "T702",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 22,
              "end_idx": 27
            },
            {
              "entity_id": "T703",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 35,
              "end_idx": 38
            },
            {
              "entity_id": "T704",
              "entity": "心血管疾病",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 46
            },
            {
              "entity_id": "T705",
              "entity": "血脂异常",
              "entity_type": "Disease",
              "start_idx": 53,
              "end_idx": 57
            },
            {
              "entity_id": "T706",
              "entity": "IR",
              "entity_type": "Disease",
              "start_idx": 58,
              "end_idx": 60
            },
            {
              "entity_id": "T707",
              "entity": "肥胖",
              "entity_type": "Disease",
              "start_idx": 61,
              "end_idx": 63
            },
            {
              "entity_id": "T708",
              "entity": "高血压",
              "entity_type": "Disease",
              "start_idx": 64,
              "end_idx": 67
            },
            {
              "entity_id": "T709",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 68,
              "end_idx": 73
            },
            {
              "entity_id": "T710",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 95,
              "end_idx": 99
            },
            {
              "entity_id": "T711",
              "entity": "血糖",
              "entity_type": "Test_items",
              "start_idx": 110,
              "end_idx": 112
            },
            {
              "entity_id": "T712",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 115,
              "end_idx": 120
            },
            {
              "entity_id": "T713",
              "entity": "IR",
              "entity_type": "Disease",
              "start_idx": 121,
              "end_idx": 123
            },
            {
              "entity_id": "T714",
              "entity": "血脂",
              "entity_type": "Test",
              "start_idx": 141,
              "end_idx": 143
            },
            {
              "entity_id": "T715",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 149,
              "end_idx": 151
            },
            {
              "entity_id": "T716",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 152,
              "end_idx": 157
            },
            {
              "entity_id": "T717",
              "entity": "TC",
              "entity_type": "Test_items",
              "start_idx": 158,
              "end_idx": 160
            },
            {
              "entity_id": "T718",
              "entity": "HDL-C",
              "entity_type": "Test_items",
              "start_idx": 164,
              "end_idx": 169
            },
            {
              "entity_id": "T719",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 182,
              "end_idx": 186
            },
            {
              "entity_id": "T720",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 22,
              "end_idx": 25
            },
            {
              "entity_id": "T721",
              "entity": "心血管",
              "entity_type": "Anatomy",
              "start_idx": 41,
              "end_idx": 44
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R313",
              "head_entity_id": "T701",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R314",
              "head_entity_id": "T720",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R315",
              "head_entity_id": "T703",
              "tail_entity_id": "T702"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R316",
              "head_entity_id": "T721",
              "tail_entity_id": "T704"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R317",
              "head_entity_id": "T710",
              "tail_entity_id": "T712"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R318",
              "head_entity_id": "T710",
              "tail_entity_id": "T713"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "48",
      "paragraph": "七、降糖外益处",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "七、降糖外益处",
          "start_idx": 0,
          "end_idx": 7,
          "entities": [],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "49",
      "paragraph": "1.在改善血脂方面的作用：二甲双胍能够改善脂肪的合成与代谢。多项研究显示，二甲双胍治疗T2DM患者，可降低患者血浆TG、LDL-C及TC水平，但对HDL-C改变不明显。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "1.在改善血脂方面的作用：二甲双胍能够改善脂肪的合成与代谢。多项研究显示，二甲双胍治疗T2DM患者，可降低患者血浆TG、LDL-C及TC水平，但对HDL-C改变不明显。",
          "start_idx": 0,
          "end_idx": 84,
          "entities": [
            {
              "entity_id": "T722",
              "entity": "血脂",
              "entity_type": "Test",
              "start_idx": 5,
              "end_idx": 7
            },
            {
              "entity_id": "T723",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17
            },
            {
              "entity_id": "T724",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 43,
              "end_idx": 47
            },
            {
              "entity_id": "T725",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 43,
              "end_idx": 45
            },
            {
              "entity_id": "T726",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 37,
              "end_idx": 41
            },
            {
              "entity_id": "T727",
              "entity": "TG",
              "entity_type": "Test_items",
              "start_idx": 57,
              "end_idx": 59
            },
            {
              "entity_id": "T728",
              "entity": "LDL-C",
              "entity_type": "Test_items",
              "start_idx": 60,
              "end_idx": 65
            },
            {
              "entity_id": "T729",
              "entity": "TC",
              "entity_type": "Test_items",
              "start_idx": 66,
              "end_idx": 68
            },
            {
              "entity_id": "T730",
              "entity": "HDL-C",
              "entity_type": "Test_items",
              "start_idx": 73,
              "end_idx": 78
            },
            {
              "entity_id": "T731",
              "entity": "改变不明显",
              "entity_type": "Test_Value",
              "start_idx": 78,
              "end_idx": 83
            }
          ],
          "relations": [
            {
              "relation_type": "Class_Disease",
              "relation_id": "R319",
              "head_entity_id": "T725",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R320",
              "head_entity_id": "T726",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R321",
              "head_entity_id": "T727",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R322",
              "head_entity_id": "T728",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R323",
              "head_entity_id": "T729",
              "tail_entity_id": "T724"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R324",
              "head_entity_id": "T730",
              "tail_entity_id": "T724"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "50",
      "paragraph": "2.在治疗NAFLD方面的作用：中华医学会肝病学分会脂肪肝和酒精性肝病学组布《中国非酒精性脂肪性肝病诊疗指南(2010年修订版)》提出：除非存在明显的肝损害(如血清转氨大于3倍正常值上限)、肝功能不全或失代偿期肝硬化等情况，否则NAFLD患者可安全使用胰岛素增敏剂(二甲双胍和噻唑烷二酮类)等药物(V级)。有14项临床研究评价了二甲双胍对NAFLD患者肝脏组织学、血清酶学和IR等指标的改善情况，所有研究均显示HOMA-IR明显改善，13项研究显示血清酶学(谷丙转氨酶、谷草转氨酶)明显下降；5项研究显示二甲双胍对肝脏炎症、脂肪变性和纤维化有改善。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "2.在治疗NAFLD方面的作用：中华医学会肝病学分会脂肪肝和酒精性肝病学组布《中国非酒精性脂肪性肝病诊疗指南(2010年修订版)》提出：除非存在明显的肝损害(如血清转氨大于3倍正常值上限)、肝功能不全或失代偿期肝硬化等情况，否则NAFLD患者可安全使用胰岛素增敏剂(二甲双胍和噻唑烷二酮类)等药物(V级)。有14项临床研究评价了二甲双胍对NAFLD患者肝脏组织学、血清酶学和IR等指标的改善情况，所有研究均显示HOMA-IR明显改善，13项研究显示血清酶学(谷丙转氨酶、谷草转氨酶)明显下降；5项研究显示二甲双胍对肝脏炎症、脂肪变性和纤维化有改善。",
          "start_idx": 0,
          "end_idx": 274,
          "entities": [
            {
              "entity_id": "T732",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 10
            },
            {
              "entity_id": "T733",
              "entity": "脂肪肝",
              "entity_type": "Disease",
              "start_idx": 26,
              "end_idx": 29
            },
            {
              "entity_id": "T734",
              "entity": "酒精性肝病",
              "entity_type": "Disease",
              "start_idx": 30,
              "end_idx": 35
            },
            {
              "entity_id": "T735",
              "entity": "非酒精性脂肪性肝病",
              "entity_type": "Disease",
              "start_idx": 41,
              "end_idx": 50
            },
            {
              "entity_id": "T736",
              "entity": "肝损害",
              "entity_type": "Disease",
              "start_idx": 75,
              "end_idx": 78
            },
            {
              "entity_id": "T737",
              "entity": "血清转氨",
              "entity_type": "Test_items",
              "start_idx": 80,
              "end_idx": 84
            },
            {
              "entity_id": "T738",
              "entity": "肝功能不全",
              "entity_type": "Disease",
              "start_idx": 95,
              "end_idx": 100
            },
            {
              "entity_id": "T739",
              "entity": "失代偿期肝硬化",
              "entity_type": "Disease",
              "start_idx": 101,
              "end_idx": 108
            },
            {
              "entity_id": "T740",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 114,
              "end_idx": 119
            },
            {
              "entity_id": "T741",
              "entity": "胰岛素增敏剂",
              "entity_type": "Drug",
              "start_idx": 126,
              "end_idx": 132
            },
            {
              "entity_id": "T742",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 133,
              "end_idx": 137
            },
            {
              "entity_id": "T743",
              "entity": "噻唑烷二酮类",
              "entity_type": "Drug",
              "start_idx": 138,
              "end_idx": 144
            },
            {
              "entity_id": "T744",
              "entity": "NAFLD",
              "entity_type": "Disease",
              "start_idx": 169,
              "end_idx": 174
            },
            {
              "entity_id": "T745",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 164,
              "end_idx": 168
            },
            {
              "entity_id": "T746",
              "entity": "IR",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 189
            },
            {
              "entity_id": "T747",
              "entity": "血清酶学",
              "entity_type": "Test",
              "start_idx": 224,
              "end_idx": 228
            },
            {
              "entity_id": "T748",
              "entity": "谷丙转氨酶",
              "entity_type": "Test_items",
              "start_idx": 229,
              "end_idx": 234
            },
            {
              "entity_id": "T749",
              "entity": "谷草转氨酶",
              "entity_type": "Test_items",
              "start_idx": 235,
              "end_idx": 240
            },
            {
              "entity_id": "T750",
              "entity": "二甲双胍",
              "entity_type": "Class",
              "start_idx": 252,
              "end_idx": 256
            },
            {
              "entity_id": "T751",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 29
            },
            {
              "entity_id": "T752",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 34
            },
            {
              "entity_id": "T753",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 48,
              "end_idx": 49
            },
            {
              "entity_id": "T754",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 75,
              "end_idx": 76
            },
            {
              "entity_id": "T755",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 95,
              "end_idx": 96
            },
            {
              "entity_id": "T756",
              "entity": "肝",
              "entity_type": "Anatomy",
              "start_idx": 105,
              "end_idx": 106
            },
            {
              "entity_id": "T757",
              "entity": "大于3倍正常值上限",
              "entity_type": "Test_Value",
              "start_idx": 84,
              "end_idx": 93
            },
            {
              "entity_id": "T758",
              "entity": "明显下降",
              "entity_type": "Test_Value",
              "start_idx": 241,
              "end_idx": 245
            },
            {
              "entity_id": "T759",
              "entity": "酒精性",
              "entity_type": "Class",
              "start_idx": 30,
              "end_idx": 33
            },
            {
              "entity_id": "T760",
              "entity": "非酒精性脂肪性",
              "entity_type": "Class",
              "start_idx": 41,
              "end_idx": 48
            },
            {
              "entity_id": "T761",
              "entity": "失代偿期",
              "entity_type": "Class",
              "start_idx": 101,
              "end_idx": 105
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R325",
              "head_entity_id": "T751",
              "tail_entity_id": "T733"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R326",
              "head_entity_id": "T752",
              "tail_entity_id": "T734"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R327",
              "head_entity_id": "T759",
              "tail_entity_id": "T734"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R328",
              "head_entity_id": "T753",
              "tail_entity_id": "T735"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R329",
              "head_entity_id": "T760",
              "tail_entity_id": "T735"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R330",
              "head_entity_id": "T754",
              "tail_entity_id": "T736"
            },
            {
              "relation_type": "Test_items_Disease",
              "relation_id": "R331",
              "head_entity_id": "T737",
              "tail_entity_id": "T736"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R332",
              "head_entity_id": "T755",
              "tail_entity_id": "T738"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R333",
              "head_entity_id": "T756",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R334",
              "head_entity_id": "T761",
              "tail_entity_id": "T739"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R335",
              "head_entity_id": "T741",
              "tail_entity_id": "T740"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R336",
              "head_entity_id": "T742",
              "tail_entity_id": "T740"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R337",
              "head_entity_id": "T743",
              "tail_entity_id": "T740"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R338",
              "head_entity_id": "T745",
              "tail_entity_id": "T744"
            }
          ]
        }
      ]
    },
    {
      "paragraph_id": "51",
      "paragraph": "3.在治疗PCOS方面的作用：PCOS不是二甲双胍的适应证，但国内外应用二甲双胍治疗PCOS已有十余年的历史。美国内分泌学会推荐二甲双胍可作为PCOS合并T2DM/IGT患者，生活方式干预(一线治疗)失败或月经不规则且无法应用避孕药(二线治疗)的情况下的一种治疗药物。循证医学证据表明二甲双胍可降低血浆胰岛素水平，增加IS，降低雄激素水平，提高雌二醇水平，改善PCOS患者的多毛症，使月经规律，诱导排卵，PCOS患者可从500mg/d开始，每周加量500mg，直到2000mg/d(分二次餐时或餐后服用)，维持数月，直至排卵，恢复月经，待发现怀孕时停药。国外甚至用到2500mg/d，安全性依然良好。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "3.在治疗PCOS方面的作用：PCOS不是二甲双胍的适应证，但国内外应用二甲双胍治疗PCOS已有十余年的历史。美国内分泌学会推荐二甲双胍可作为PCOS合并T2DM/IGT患者，生活方式干预(一线治疗)失败或月经不规则且无法应用避孕药(二线治疗)的情况下的一种治疗药物。循证医学证据表明二甲双胍可降低血浆胰岛素水平，增加IS，降低雄激素水平，提高雌二醇水平，改善PCOS患者的多毛症，使月经规律，诱导排卵，PCOS患者可从500mg/d开始，每周加量500mg，直到2000mg/d(分二次餐时或餐后服用)，维持数月，直至排卵，恢复月经，待发现怀孕时停药。",
          "start_idx": 0,
          "end_idx": 277,
          "entities": [
            {
              "entity_id": "T762",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 5,
              "end_idx": 9
            },
            {
              "entity_id": "T763",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T764",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T765",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 36,
              "end_idx": 40
            },
            {
              "entity_id": "T766",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 42,
              "end_idx": 46
            },
            {
              "entity_id": "T767",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 71,
              "end_idx": 75
            },
            {
              "entity_id": "T768",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 77,
              "end_idx": 81
            },
            {
              "entity_id": "T769",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 77,
              "end_idx": 79
            },
            {
              "entity_id": "T770",
              "entity": "IGT",
              "entity_type": "Disease",
              "start_idx": 82,
              "end_idx": 85
            },
            {
              "entity_id": "T771",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 64,
              "end_idx": 68
            },
            {
              "entity_id": "T772",
              "entity": "生活方式干预",
              "entity_type": "Treatment",
              "start_idx": 88,
              "end_idx": 94
            },
            {
              "entity_id": "T773",
              "entity": "避孕药",
              "entity_type": "Drug",
              "start_idx": 113,
              "end_idx": 116
            },
            {
              "entity_id": "T774",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 142,
              "end_idx": 146
            },
            {
              "entity_id": "T775",
              "entity": "胰岛素水平",
              "entity_type": "Test_items",
              "start_idx": 151,
              "end_idx": 156
            },
            {
              "entity_id": "T776",
              "entity": "雄激素",
              "entity_type": "Test_items",
              "start_idx": 164,
              "end_idx": 167
            },
            {
              "entity_id": "T777",
              "entity": "雌二醇",
              "entity_type": "Test_items",
              "start_idx": 172,
              "end_idx": 175
            },
            {
              "entity_id": "T778",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 180,
              "end_idx": 184
            },
            {
              "entity_id": "T779",
              "entity": "多毛症",
              "entity_type": "Disease",
              "start_idx": 187,
              "end_idx": 190
            },
            {
              "entity_id": "T780",
              "entity": "PCOS",
              "entity_type": "Disease",
              "start_idx": 202,
              "end_idx": 206
            },
            {
              "entity_id": "T781",
              "entity": "500mg/d",
              "entity_type": "Amount",
              "start_idx": 210,
              "end_idx": 217
            },
            {
              "entity_id": "T782",
              "entity": "每周加量500mg",
              "entity_type": "Amount",
              "start_idx": 220,
              "end_idx": 229
            },
            {
              "entity_id": "T783",
              "entity": "直到2000mg/d",
              "entity_type": "Amount",
              "start_idx": 230,
              "end_idx": 240
            },
            {
              "entity_id": "T784",
              "entity": "分二次",
              "entity_type": "Frequency",
              "start_idx": 241,
              "end_idx": 244
            },
            {
              "entity_id": "T786",
              "entity": "餐时或餐后服用",
              "entity_type": "Method",
              "start_idx": 244,
              "end_idx": 251
            }
          ],
          "relations": [
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R339",
              "head_entity_id": "T765",
              "tail_entity_id": "T766"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R340",
              "head_entity_id": "T771",
              "tail_entity_id": "T767"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R341",
              "head_entity_id": "T772",
              "tail_entity_id": "T767"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R342",
              "head_entity_id": "T769",
              "tail_entity_id": "T768"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R343",
              "head_entity_id": "T771",
              "tail_entity_id": "T768"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R344",
              "head_entity_id": "T772",
              "tail_entity_id": "T768"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R345",
              "head_entity_id": "T771",
              "tail_entity_id": "T770"
            },
            {
              "relation_type": "Treatment_Disease",
              "relation_id": "R346",
              "head_entity_id": "T772",
              "tail_entity_id": "T770"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R347",
              "head_entity_id": "T774",
              "tail_entity_id": "T780"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R348",
              "head_entity_id": "T781",
              "tail_entity_id": "T774"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R349",
              "head_entity_id": "T782",
              "tail_entity_id": "T774"
            },
            {
              "relation_type": "Amount_Drug",
              "relation_id": "R350",
              "head_entity_id": "T783",
              "tail_entity_id": "T774"
            },
            {
              "relation_type": "Frequency_Drug",
              "relation_id": "R351",
              "head_entity_id": "T784",
              "tail_entity_id": "T774"
            },
            {
              "relation_type": "Method_Drug",
              "relation_id": "R352",
              "head_entity_id": "T786",
              "tail_entity_id": "T774"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "国外甚至用到2500mg/d，安全性依然良好。",
          "start_idx": 277,
          "end_idx": 300,
          "entities": [
            {
              "entity_id": "T785",
              "entity": "2500mg/d",
              "entity_type": "Amount",
              "start_idx": 6,
              "end_idx": 14
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "52",
      "paragraph": "4.抗肿瘤作用：糖尿病可能是多种肿瘤，如乳腺癌、胰腺癌、结直肠癌、子宫内膜癌等的危险因素。多项研究显示，二甲双胍可激活AMP激活的蛋白激(AMPK)通路。而AMPK通路的激活除了影响代谢外，也可能抑制肿瘤的发生和发展。英国一项大型病例对照研究显示，二甲双胍治疗与癌症的危险性下降具有相关性，并观察到随着使用时间的延长和使用次数的增加，二甲双胍的保护效应具有逐渐增强的趋势(Ⅱ级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "4.抗肿瘤作用：糖尿病可能是多种肿瘤，如乳腺癌、胰腺癌、结直肠癌、子宫内膜癌等的危险因素。多项研究显示，二甲双胍可激活AMP激活的蛋白激(AMPK)通路。",
          "start_idx": 0,
          "end_idx": 77,
          "entities": [
            {
              "entity_id": "T787",
              "entity": "糖尿病",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 11
            },
            {
              "entity_id": "T788",
              "entity": "乳腺癌",
              "entity_type": "Disease",
              "start_idx": 20,
              "end_idx": 23
            },
            {
              "entity_id": "T789",
              "entity": "胰腺癌",
              "entity_type": "Disease",
              "start_idx": 24,
              "end_idx": 27
            },
            {
              "entity_id": "T790",
              "entity": "结直肠癌",
              "entity_type": "Disease",
              "start_idx": 28,
              "end_idx": 32
            },
            {
              "entity_id": "T791",
              "entity": "子宫内膜癌",
              "entity_type": "Disease",
              "start_idx": 33,
              "end_idx": 38
            },
            {
              "entity_id": "T792",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 52,
              "end_idx": 56
            },
            {
              "entity_id": "T795",
              "entity": "乳腺",
              "entity_type": "Anatomy",
              "start_idx": 20,
              "end_idx": 22
            },
            {
              "entity_id": "T796",
              "entity": "胰腺",
              "entity_type": "Anatomy",
              "start_idx": 24,
              "end_idx": 26
            },
            {
              "entity_id": "T797",
              "entity": "结直肠",
              "entity_type": "Anatomy",
              "start_idx": 28,
              "end_idx": 31
            },
            {
              "entity_id": "T798",
              "entity": "子宫内膜",
              "entity_type": "Anatomy",
              "start_idx": 33,
              "end_idx": 37
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R353",
              "head_entity_id": "T795",
              "tail_entity_id": "T788"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R354",
              "head_entity_id": "T796",
              "tail_entity_id": "T789"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R355",
              "head_entity_id": "T797",
              "tail_entity_id": "T790"
            },
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R356",
              "head_entity_id": "T798",
              "tail_entity_id": "T791"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "而AMPK通路的激活除了影响代谢外，也可能抑制肿瘤的发生和发展。",
          "start_idx": 77,
          "end_idx": 109,
          "entities": [],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "英国一项大型病例对照研究显示，二甲双胍治疗与癌症的危险性下降具有相关性，并观察到随着使用时间的延长和使用次数的增加，二甲双胍的保护效应具有逐渐增强的趋势(Ⅱ级)。",
          "start_idx": 109,
          "end_idx": 190,
          "entities": [
            {
              "entity_id": "T793",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 15,
              "end_idx": 19
            },
            {
              "entity_id": "T794",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 58,
              "end_idx": 62
            }
          ],
          "relations": []
        }
      ]
    },
    {
      "paragraph_id": "34",
      "paragraph": "6.肾功能不全的T2DM患者使用注意事项：二甲双胍本身不会对肾功能有影响，但临床存在仅根据蛋白尿就停用二甲双胍的使用误区。建议根据eGFR的水平调整二甲双胍的使用。患者eGFR≥60ml/(min·1.73m2)无需减量，eGFR 45~60ml/(min·1.73m2)时减量，当eGFR<45ml/(min·1.73m2)时停用(V级)。",
      "sentences": [
        {
          "sentence_id": "0",
          "sentence": "6.肾功能不全的T2DM患者使用注意事项：二甲双胍本身不会对肾功能有影响，但临床存在仅根据蛋白尿就停用二甲双胍的使用误区。",
          "start_idx": 0,
          "end_idx": 61,
          "entities": [
            {
              "entity_id": "T799",
              "entity": "肾功能不全",
              "entity_type": "Disease",
              "start_idx": 2,
              "end_idx": 7
            },
            {
              "entity_id": "T800",
              "entity": "T2DM",
              "entity_type": "Disease",
              "start_idx": 8,
              "end_idx": 12
            },
            {
              "entity_id": "T801",
              "entity": "T2",
              "entity_type": "Class",
              "start_idx": 8,
              "end_idx": 10
            },
            {
              "entity_id": "T802",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 21,
              "end_idx": 25
            },
            {
              "entity_id": "T803",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 51,
              "end_idx": 55
            },
            {
              "entity_id": "T812",
              "entity": "蛋白尿",
              "entity_type": "Disease",
              "start_idx": 45,
              "end_idx": 48
            },
            {
              "entity_id": "T813",
              "entity": "肾",
              "entity_type": "Anatomy",
              "start_idx": 2,
              "end_idx": 3
            }
          ],
          "relations": [
            {
              "relation_type": "Anatomy_Disease",
              "relation_id": "R357",
              "head_entity_id": "T813",
              "tail_entity_id": "T799"
            },
            {
              "relation_type": "Class_Disease",
              "relation_id": "R358",
              "head_entity_id": "T801",
              "tail_entity_id": "T800"
            },
            {
              "relation_type": "Drug_Disease",
              "relation_id": "R359",
              "head_entity_id": "T802",
              "tail_entity_id": "T800"
            }
          ]
        },
        {
          "sentence_id": "1",
          "sentence": "建议根据eGFR的水平调整二甲双胍的使用。",
          "start_idx": 61,
          "end_idx": 82,
          "entities": [
            {
              "entity_id": "T804",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 4,
              "end_idx": 8
            },
            {
              "entity_id": "T805",
              "entity": "二甲双胍",
              "entity_type": "Drug",
              "start_idx": 13,
              "end_idx": 17
            }
          ],
          "relations": []
        },
        {
          "sentence_id": "2",
          "sentence": "患者eGFR≥60ml/(min·1.73m2)无需减量，eGFR 45~60ml/(min·1.73m2)时减量，当eGFR<45ml/(min·1.73m2)时停用(V级)。",
          "start_idx": 82,
          "end_idx": 171,
          "entities": [
            {
              "entity_id": "T806",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 2,
              "end_idx": 6
            },
            {
              "entity_id": "T807",
              "entity": "≥60ml/(min·1.73m2)",
              "entity_type": "Test_Value",
              "start_idx": 6,
              "end_idx": 24
            },
            {
              "entity_id": "T808",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 29,
              "end_idx": 33
            },
            {
              "entity_id": "T809",
              "entity": "45~60ml/(min·1.73m2)",
              "entity_type": "Test_Value",
              "start_idx": 34,
              "end_idx": 54
            },
            {
              "entity_id": "T810",
              "entity": "eGFR",
              "entity_type": "Test_items",
              "start_idx": 59,
              "end_idx": 63
            },
            {
              "entity_id": "T811",
              "entity": "<45ml/(min·1.73m2)",
              "entity_type": "Test_Value",
              "start_idx": 63,
              "end_idx": 81
            }
          ],
          "relations": []
        }
      ]
    }
  ]
}